role of pentose phosphates in nucleoside catabolism and interconversion by BALESTRI, FRANCESCO
Università degli Studi di Pisa 
 
Doctorate Course in Molecular 
Biotechnology, XX cycle 
 
“ROLE OF PENTOSE PHOSPHATES IN 
NUCLEOSIDE CATABOLISM AND 
INTERCONVERSION” 
 
Tutor: 
Prof.ssa Marcella Camici 
 
    
   Student: 
Dr. Francesco Balestri 
 
 
 
 
 
 
 1 
 
 
 
 
 
 
 
Desidero ringraziare tutte le persone che lavorano 
presso la sezione di Biochimica del Dipartimento di 
Biologia per l’aiuto e la disponibilità che mi hanno 
dato.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2 
 ABSTRACT 
 
 
Purine and pyrimidine are the basic constituents of the polynucleotides DNA and 
RNA; they are considered of predominant importance also as information molecules, 
energy transducers, antioxidants and they have also important roles in cellular 
signalling processes. Reports suggest protective roles for purines and pyrimidines in 
various pathological conditions ranging from cancer, to ischemia-associated injury, 
traumatic tissue damage, bone resorption, stress and haemorrhagic shock. 
Mitochondrial oxidative phosphorylation, along with glycolysis, is essential for the 
maintenance of brain ATP levels. The depletion of cellular energy sources and 
reduction of ATP synthesis during ischemia or brain insults cause the loss of cellular 
homeostasis, which eventually leads to irreversible cellular damage. Some papers 
have shown that adenosine and inosine protect neural cells during hypoxia/ischemia 
in vivo and in vitro. While in some cases the action of adenosine is receptor-
mediated, to explain the effect of its deamination product, inosine, the contribution of 
hitherto unknown specific receptors has been invoked. On the other hand, several 
papers report a receptor-independent mechanism of nucleoside action, which 
indicates that nucleosides donate their ribose moiety to the pentose phosphate 
pathway, where it is converted to intermediates for entry into the glycolytic pathway 
for anaerobic production of ATP. 
To shed light on the mechanism underlying the protective role of purine and 
pyrimidine during ischemia or brain insults, we have used a human astrocytoma cell 
line (ADF) which has been subjected to metabolic stress conditions by exclusion of 
glucose and pre-incubation with oligomycin (an inhibitor of oxidative 
phosphorylation). This treatment brings about a depletion of the ATP pool, with a 
concomitant increase in the AMP levels, which results in a significant decrease of the 
adenylate energy charge. The presence of purine nucleosides in the culture medium 
preserves the adenylate energy charge, and improves cell viability. Besides purine 
nucleosides, also pyrimidine nucleosides, such as uridine and, to a lesser extent, 
cytidine, are able to preserve the ATP pool. The determination of lactate in the 
incubation medium indicates that nucleosides can preserve the ATP pool through 
anaerobic glycolysis, thus pointing to a relevant role of the phosphorolytic cleavage 
of the N-glycosidic bond of nucleosides which generates, without energy expense, 
the phosphorylated pentose, which through the pentose phosphate pathway and 
glycolysis can be converted to energetic intermediates also in the absence of oxygen. 
In fact, ADF cells possess both purine nucleoside phosphorylase and uridine 
phosphorylase activities. The results of this research line have been published in 
Neurochem. Int. 50: 517-523 (2007) (see attached). 
Additionally, the phosphorylated ribose moiety of nucleosides may be used itself 
for the salvage of pyrimidine nucleosides or can be converted by 5-phosphoribosyl-
1-pyrophoshate (PRPP) synthetase, into PRPP which is an essential compound for 
the salvage pathway of purines.  
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In fact, adenine and hypoxanthine, in the presence of PRPP, are substrates of 
adenine phosphoribosyltransferase (APRT) and hypoxanthine-guanine 
phosphoribosyltransferase (HPRT), which catalyze the formation of adenosine and 
inosine monophosphate, respectively (purine salvage pathway).  
On the other hand, uridine can be both phosphorolytically cleaved by uridine 
phosphorylase (UPase) to ribose-1-phosphate (Rib-1-P) and the uracil base, or can be 
converted by uridine kinase (UK) into uridine nucleotides (pyrimidine salvage 
pathway). It has been shown that disruption of uridine homeostasis by deletion of rat 
UPase gene leads to disorders of both pyrimidine and purine nucleotide synthesis, 
thus suggesting a linkage between the two metabolic processes. We have 
hypothesized that the UPase–UK enzyme system, which maintains uridine 
homeostasis, regulates the processes of both purine and pyrimidine salvage. 
Exogenous uridine and, to a lesser extent inosine, activate the salvage of exogenous 
adenine in human astrocytoma cells in a concentration-dependent manner. Moreover, 
uridine is also able to activate the salvage of exogenous hypoxanthine. When uridine 
and inosine are present, more Rib-1-P becomes available, through the action of 
UPase and purine nucleoside phosphorylase (PNP), for the PRPP-mediated adenine 
and hypoxanthine salvage. Exogenously added adenine partially inhibits uridine 
salvage; in fact, the increased utilization of PRPP exerted by added adenine, might 
further favour uridine phosphorolysis, thus subtracting the pyrimidine nucleoside to 
the UK action. Moreover, exogenous inosine favours not only uracil salvage but also 
5-FU activation through a Rib-1-P-mediated process. The pre-treatment of the cells 
with cytidine brings about an inhibition of the pyrimidine salvage and an activation 
of the purine salvage in the presence of uridine as ribose phosphate donor. In fact, 
cytidine enters the cells and is converted into CTP which inhibits UK and this 
inhibition causes a shift of the equilibrium of the reversible UPase reaction towards 
uridine phosphorolysis. The Rib-1-P formed is then converted into PRPP, which is 
used for the purine salvage synthesis. Conversely, when the concentration of CTP is 
relatively low, the fully active UK, which catalyzes a virtual irreversible reaction, 
drives uridine towards uridine nucleotide formation, thus lowering the rate of purine 
synthesis. Therefore, the ribose phosphate stemming from the phosphorolysis of 
purine and pyrimidine nucleosides not only can be converted into energetic 
intermediates in order to restore the ATP pool during cellular stress but it can be 
considered a link between the purine and pyrimidine salvage and these two processes 
are regulated at the level of UPase–UK enzyme system by the relative pyrimidine 
nucleoside triphosphate concentration. The results of this research line have been 
published in Neurochem. Int. 51: 517-523 (2007) (see attached). 
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ABBREVIATIONS 
 
5-(phenylthio) acyclouridine (PTAU) 
5-phosphoribosyl-1-pyrohosphate (PRPP) 
5- fluorouracil (5-FU) 
8-cyclopentenyl-1,3-dipropylxanthine (DPCPX) 
Adenosine (Ado) 
Adenine (Ade) 
Adenine phosphorybosiltransferase (APRT) 
Adenosine 5’-diphosphate (ADP) 
Adenosine 5’-monophosphate (AMP) 
Adenosine 5'-triphosphate (ATP) 
Adenosine deaminase (ADA) 
Adenosine kinase (AK).  
Adenosine phosphoribosyltransferase (APRT) 
Adenosine receptors (ARs)  
Astrocyte-neuron-lactate shuttle (ANLSH) 
Blood-brain barrier (BBB) 
Carbamoyl phosphate II (CPII) 
Central nervous system (CNS) 
Citric acid cycle (TCA) 
Cyclic AMP (cAMP) 
Cyclic GMP (cGMP) 
Cytidine (Ctd) 
Cytosine (Cyt) 
Cytidine 5’-monophosphate (CMP) 
Cytidine 5’-diphosphate (CDP) 
Cytidine 5’-triphosphate (CTP) 
Cytidine kinase (CK) 
Cytosolic 5’-nucleotidase type II (cN-II) 
Concentrative nucleoside transporters (CNT) 
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Deoxyadenosine (dAdo) 
Deoxycytidine monophosphate (dCMP) 
Deoxycoformycin (dCF) 
Deoxyinosine (dIno)  
Deoxyribonucleic acid (DNA) 
Deoxythimidine monophosphate (dTMP) 
Dihydropyrimidine dehydrogenase (DPD) 
Dopamine receptors (DRs) 
Dulbecco’s modified Eagle medium without glucose (DMEM)  
Dulbecco’s phosphate buffered saline (PBS) 
Ecto-nucleoside triphosphatase (E-NTPase) 
Equilibrative nucleoside transporters (ENT) 
Flavin adenin dinucleotide (FAD) 
Fibroblast growth factor (FGF) 
Foetal bovine serum (FBS) 
Glial-derived neurotrophic factor (GDNF) 
Glyceraldehyde 3-P (Gly 3-P) 
Glucose (Glc) 
Glucose transporter (GLUT) 
Glutathione (GSH) 
G protein-coupled membrane receptors (GPCRs) 
Guanine (Gua) 
Guanosine (Guo) 
Guanosine 5’-monophosphate (GMP) 
Guanosine 5’-triphosphate (GTP) 
High Pressure Liquid Chromatography (HPLC) 
Hypoxanthine (Hyp)  
Hypoxanthine-guanine phosphoribosyl transferase (HGPRT) 
Human astrocytoma cell line (ADF) 
Inosine (Ino)  
Inosine monophosphate (IMP) 
Inosine nucleoside cycle (INC) 
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Interleukin-6 (IL-6) 
Lactate dehydrogenase (LDH) 
LDH-5 (lactate dehydrogenase-5) 
Lesch-Nyhan syndrome (LNS) 
Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) 
Mitogen-activated protein kinases (MAPK) 
Monocarboxilate transporter (MCT) 
Nerve growth factor (NGF) 
Neurite growth-promoting factors 1 (NEGF1) 
Nicotinamide adenine dinucleotide (NAD)  
Nicotinamide adenine dinucleotide phosphate (NADP) 
Nitric oxide (NO) 
Nitric oxide synthase (iNOS) 
Nitrobenzylthioinosine (NBTI) 
N-methyl D-aspartate (NMDA) 
Orotidine 5’-monophosphate (OMP) 
Phosphatidylcholine (PC) 
Phosphatidylethanolamine (PE) 
Phosphoribosyltransferase (OPRT)  
Protein kinase A (PKA) 
Protein kinase C (PKC) 
Purine nucleoside phosphorylase (PNP) 
Purinergic receptors (P receptors) 
Ribonucleic acid (RNA) 
Ribose (Rib) 
Ribose-1-phosphate (Rib1P) 
Ribose 5-phosphate (Rib5P) 
Reactive oxygen species (ROS) 
Thymidine 5’-monophosphate (TMP) 
Thymidine phosphorylase (TP) 
Total adenine nucleotide (TAN) 
Total uracil nucleotide (TUN) 
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Tumor necrosis factor (TNF) 
Uracil (Ura) 
Uridine (Urd) 
Uridine diphosphoglucose (UDPG) 
Uridine 5’-diphosphate (UDP) 
Uridine 5’-monophosphate (UMP)  
Uridine 5’-triphosphate (UTP)  
Uridine monophosphate hydrolase (UMPH) 
Uridine monophosphate synthase (UMPS) 
Uridine kinase (UK) 
Uridine phosphorylase (UPase) 
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  INTRODUCTION 
 
 
1 Astrocyte cells: morphology, physiology and metabolism 
 
1.1 Cells types in the central nervous system 
 
The central nervous system (CNS) is composed of a variety of different cell types, 
which depend on each other for survival and functional integrity, and have the 
capacity for intercellular communication. 
The mammalian CNS consists of two main cell types, neurons and glia. Neurons 
are directly involved in electrical transmission and information processing, and glia 
carry out many indispensable functions, both in development and during the normal 
function of the mature CNS. 
Glial cells are numerically the dominant cell type in the central and peripheral 
nervous system. They are intermixed with the nerve cells and are found in intimate 
contacts with neuronal cell bodies, dendrites, axons and synaptic contacts. Like 
neurons, glial cells are a heterogeneous population of cells that differ in 
developmental origin, molecular composition, structure and activity. When these 
cells were first discovered some 150 years ago, they were viewed as a type of 
connective tissue support for nerve cells. They were considered to assume a passive 
role of structural support for neurons and to provide a preferential, but metabolically 
inert, route for the passage of glucose from the circulation to neurons. More recent 
reports, however suggest that they have much more important and dynamic functions 
in the brain and other parts of the nervous system: they respond to synaptic activity 
and they play an important role in the communication network within the central 
nervous system (Voutsinos-Porche et al., 2003; Jessen et al., 2006). 
Glial cells in the CNS are represented by three main types: macroglia (astroglia, 
oligodendroglia) and microglia. The macroglial cells are of ectodermal origin, 
whereas microglia stem from the mesoderm; the functions of oligodendrocytes and 
microglial cells are rather well defined: the oligodendrocytes are responsible for 
myelination and metabolic support of axons, whereas the microglial cells are 
involved in brain immune reactivity and defence. In particular,microglia phagocytize 
foreign particles and cellular debris, and produce many immune factors. 
 
 
1.2 Astrocyte cells: morphology 
 
Astrocytes (Fig.1) are the most abundant type of glial cell, and in contrast with 
microglia, are much more intimately involved in the formation of CNS cellular 
circuits and in information processing in the brain (Verkhratsky et al., 2006). 
There are generally two types of astrocytes, protoplasmic and fibrous, similar in 
function but distinct in morphology and distribution. Protoplasmic astrocytes have 
short, thick, highly branched processes and are typically found in grey matter. 
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Fibrous astrocytes have long, thin, less branched processes and are more commonly 
found in white matter. 
 
Fig.1 Culture of astrocyte cells 
 
Astrocytes participate in numerous functions including structural and metabolic 
support for neurons, homeostatic and signalling functions in the brain including 
synthesis of the citric acid cycle (TCA) intermediates, regulation of extracellular 
glutamate and cation levels, energy storage of glycogen and regulation of blood flow 
(Mulligan et al., 2004). 
Neuronal networks are physically discontinuous, with neurons being separate 
entities. The integration and communication within these neuronal networks is 
provided by specialised structures, the synapses, which are considered the substrates 
of chemical neurotransmission (Verkhratsky et al., 2006). 
Because of their capacity to detect and respond to neuronal activity, glial cells, 
and in particular astrocytes, may be an integral part of the communication network 
within the central nervous system. Among their new emerging roles, glial cells have 
been shown to enhance synapse number and spontaneous synaptic activity between 
developing neurons in culture and to play a role in the stabilization and maintenance 
of synapses (Voutsinos-Porche et al., 2003). The modulation of synaptic transmission 
by glial cells has been also described at the neuromuscular junction, in hippocampal 
cultures, and in the retina (Voutsinos-Porche et al., 2003). 
Astroglia divide the grey matter into distinct compartments, and within each of 
these compartments, a single astrocyte forms contacts with all neuronal membranes 
and synapses residing within its confines. These contacts are created by fine 
astroglial processes, called filopodia and lamellipodia. These are highly dynamic 
structures: lamellipodia being able to glide along neuronal surfaces, whereas 
filopodia are rapidly extended from the astroglial processes and surround synapses 
(Verkhratsky et al., 2006). Mitochondria are too large to fit within fine processes, 
and the filopodia are, therefore, likely to be highly dependent on glycolytic 
metabolism of glucose and glycogen as local fuel sources. Thus, glycolysis is 
expected to predominate in astrocytic peripheral fine processes that are too small for 
mitochondria, whereas oxidative metabolism would be carried out in the soma, larger 
processes and end-feet (Dienel et al., 2005). 
Astrocyte cells not only form interactions with neurons but they also provide a 
link between neurons and blood capillaries. In fact the end-feet of several astrocytes 
cover the capillary wall in order to form a glial-vascular interface which is a part of 
the blood-brain barrier (BBB) (Verkhratsky et al., 2006). These processes express 
glucose transporters suggesting that astrocytes may constitute a privileged site of 
glucose uptake as it penetrates within the brain parenchyma (Morgello et al., 1995).  
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Some astrocyte processes contact blood–brain barrier, also in order to protect the 
CNS from being exposed to endogenous neurotoxins present in the general 
circulation (Alberdi et al., 2005).  
 
1.3 Astrocytoma cells 
 
Astrocytomas are primary intracranial tumours derived from astrocyte cells of the 
brain. They may arise in the cerebral hemispheres, in the posterior fossa, in the optic 
nerve, and rarely, the spinal cord (Mangiardi et al., 1990). Well-differentiated 
astrocytomas constitute about 25 to 30% of cerebral gliomas. They have a 
predilection for the cerebrum, cerebellum, hypothalamus, pons, and optic nerve and 
chiasm. 
Astrocytic tumours are the most common type of gliomas. They can occur in most 
parts of the brain and occasionally in the spinal cord. However, they most commonly 
grow in the main part of the brain, the cerebrum (Mangiardi et al., 1990). People of 
any age can develop an astrocytic tumour, but those in the cerebrum are more 
common in adults, and the chance of developing one increases as people get older. 
Astrocytic tumours in the cerebellum are more common in children or young people 
(Mangiardi et al., 1990). Regional effects of astrocytomas include compression, 
invasion, and destruction of brain parenchyma. Arterial and venous hypoxia, 
competition for nutrients, release of metabolic end products (eg, free radicals, altered 
electrolytes, neurotransmitters), and release and recruitment of cellular mediators 
(eg, cytokines) disrupt normal parenchymal function (Mangiardi et al., 1990). The 
astrocytoma cells prefer to produce ATP through glycolysis rather than oxidative 
phosphorylation and the cells continue with the lactate production also when oxygen 
is present (Mangiardi et al., 1990). In fact in these cells the Krebs cycle and the 
oxidative phosphorylation seem to be partially blocked; moreover in the astrocytoma 
cells there is a decrease of the mitochondrial number in comparison with normal cells 
(Mangiardi et al., 1990). On the other hand in these cells the pentose phosphate 
pathway is more active compared to normal cells; therefore these cells are able to 
produce a great amount of ribose 5-P which is absolutely necessary for 5-
phosphoribosyl-1-pyrohosphate (PRPP) production which is a common substrate for 
the purine and pyrimidine synthesis (Mangiardi et al.,1990). Astrocytoma cells show 
a relatively low activity of purine metabolism when compared with normal brain and 
non-glial brain neoplasms (Bardot et al., 1994). 
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2. Energetic metabolism in the central nervous system 
 
2.1 Glucose 
 
Glucose (Glc), a monosaccharide, is the most important carbohydrate in biology. 
The cell uses it as a source of energy and metabolic intermediates. Glucose is one of 
the main products of photosynthesis and starts cellular respiration in both 
prokaryotes and eukaryotes. Glucose is considered the major if not exclusive energy 
source for mammalian brain and a continuous supply of this substrate is essential to 
maintain normal cerebral function. This indicates that oxidative phosphorylation is 
the most important process used to generate from glucose the energy necessary to 
sustain the brain functions (Ioudina et al., 2004). Glucose crosses the blood-brain 
barrier and enters neurons or glial cells via specific glucose transporters and is 
metabolized via glycolysis and the Krebs cycle in order to produce ATP. The brain is 
able to maintain cerebral energy metabolism due, in part, to the relatively high 
glucose concentration in the plasma and the presence of glucose transporters in the 
capillary endothelial cell, glial cells and neurons. In the rat brain, extracellular 
glucose concentration ranges from 0.7 to 2.5 mM, corresponding to plasma glucose 
levels. The total glucose deprivation leads to neuronal degeneration while the effects 
of a moderate deprivation of glucose are not well understood (Ioudina et al., 2004). 
In the cells grown in a low glucose media there is a decrease in the cellular ATP and 
cell viability and an increase of caspase-3 activity which leads to apoptosis and 
therefore the glucose deprivation could be a serious risk factor that potentiates the 
pathophysiological consequences of certain neurodegenerative diseases (Ioudina et 
al., 2004).  
During the physiologic brain activity, glucose crosses the blood-brain barrier via 
facilitative transporters named glucose transporter 1 (GLUT1). Once within the brain 
parenchyma, it is taken up by both neurons and astrocytes via glucose transporter 3 
(GLUT3) and GLUT1, respectively. In particular, about half of the glucose leaving 
the capillaries crosses the extracellular space and directly enters neurons; the other 
half is taken up by astrocytes (Nehlig et al., 2007). GLUT 1 is expressed in all cell 
types, and it is the only glucose transporter identified in the brain. In the brain it is 
present at a high concentration at the blood-brain barrier as well as in parenchymal 
cells, most likely in astrocytes. In particular, GLUT 1 is detected in astrocytic end-
feet around blood vessels, and in astrocytic cell bodies and processes in both grey 
and white matter. GLUT 3, in the brain, is expressed in neurons; in particular is 
located primarily in pre- and postsynaptic nerve endings and in small neuronal 
processes (Maher et al., 1994).  
In each cell type, glucose is metabolized via glycolysis into pyruvate, leading to 
the formation of 2 ATP. Then, pyruvate is further metabolized via the TCA cycle, 
and in conjunction with oxidative phosphorylation using oxygen provided by the 
blood circulation, it generates 30 ATP (Maher et al., 1994). However calculations 
suggest that neurons consume more energy than do astrocytes, implying that 
astrocytes transfer an intermediate substrate to neurons.  
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Experimental approaches in vitro on the honeybee drone retina and on the isolated 
vagus nerve also point to a continuous transfer of brain intermediate metabolites in 
vivo and in vitro as is well documented in the ANLSH theory (Nehlig et al., 2007). 
 
2.2 Astrocyte-neuron-lactate shuttle theory (ANLSH) 
 
There is controversy at present concerning the metabolic changes that accompany 
neuronal activation and the energy substrate used by the activated neurons. The 
traditional theory considers the glucose as the exclusive compound involved in the 
production of energy necessary for neuronal and astrocyte survival. As already 
described, glucose is utilized by both neurons and astrocytes in order to produce 
pyruvate which can enters the TCA cycle and oxidative phosphorylation for ATP 
production.  
Another theory concerning the glucose utilization by neuronal and astrocyte cells 
is the astrocyte-neuron-lactate shuttle (ANLSH), revealed for the first time by 
Pellerin and Magistretti (1999). The ANLSH model postulates that activated neurons 
use lactate which is provided by astrocytes (Fig.2). It is well known that the major 
amount of energy consumption (90-95%) can be attributed to neurons whereas glial 
cells contribute only in a small fraction (5-10%) under normal level of activity; on 
the other hand, several studies reveal that 80% of glucose utilization is taking place 
in glial cells. And so, to fulfil the greater energy needs of neurons, glial cells must 
release a metabolic intermediate from glucose that will be eventually taken up and 
oxidized by neurons (Pellerin and Magistretti, 1999, 2004).  
 
 
 
Fig.2 Schematic illustration of the astrocyte-neuron-lactate shuttle (ANLSH) 
(Image taken from www.nature.com) 
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It has been known that glial cells and in particular astrocytes are able to produce a 
large amount of lactate in the presence of normal oxygen levels; this lactate 
production is enhanced during a neuronal synaptic activity at glutamatergic synapses: 
after this stimulation there is a significant increase of the extracellular 
neurotransmitter glutamate which, via glutamate transporters (GLAST or GLT1), 
enters astrocyte cells and causes an increase in both glucose utilization and lactate 
production. In addition, glutamate causes a rapid stimulation of glucose transport in 
astrocytes and it is considered the fastest glucose transport response ever recorded in 
any other cell type. Lines of evidence of this mechanism have been provided in vivo: 
in knockout mice for either GLAST or GLT1 transporters, a significant reduction of 
the glucose utilization during a neuronal stimulation has been observed (Pellerin and 
Magistretti, 1999, 2004).  
Glutamate transporters operate by coupling glutamate transport with the Na+ 
gradient. For each glutamate molecule transported within the cell, three Na+ (or two 
Na+ and one H+) ions are cotransported together with one proton while one K+ ion 
and one OH- is extruded. As a consequence, a significant Na+ influx occurs in 
astrocytes, with an accumulation of Na+ inside the cell accompanied by an 
intracellular acidification and extracellular alkalinization (Danbolt et al., 2001).  
Changes in the intracellular sodium concentration modulate the activity of the α2 
isoform of the Na+, K+-ATPase pump and this correlation is demonstrated in several 
cell types and also in the astrocyte cells (Pellerin and Magistretti, 1999, 2004). The 
Na+ influx not only activates the Na+-K+ ATPase but also the enzyme glutamine 
synthase which leads to the production of glutamine with a concomitant increase of 
ADP, Pi and AMP levels and a decrease of levels of ATP. As a consequence, an 
activation of anaerobic glycolysis, which generates lactate from glucose by LDH-5 
(lactate dehydrogenase-5) and restores the ATP levels, is observed (Pellerin and 
Magistretti, 1999, 2004).  
The lactate is transported across the glial membrane and leaves the astrocytes by a 
specific monocarboxylate transporter (MCT1); once in the extracellular space, the 
increased concentration gradient leads to its net transport into neurons by its own 
specific monocarboxylate transporter MCT2. The increased lactate in the neurons is 
converted to pyruvate via LDH-1 (lactate dehydrogenase-1), which enters the TCA 
cycle and oxidative phosphorylation with the final ATP production (Pellerin and 
Magistretti, 1999, 2004). The generation of ATP serves also for the production of the 
neurotransmitter glutamate. Therefore, in this theory there is a metabolic coupling 
between astrocytes and neurons in brain tissue and the neurons should prefer lactate 
to glucose as substrate, particularly during periods of intense neuronal activity 
(Pellerin and Magistretti, 1999, 2004). 
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2.3 Glycogen 
 
Glycogen is a polysaccharide that is the principal storage form of glucose in 
animal cells. Glycogen energy stores in the brain are made exclusively by astrocytes 
which express the gluconeogenesis and glycogenolysis enzymes while neurons do 
not have these enzymes (Maher et al., 1994). Glycogen is a fuel in the normal 
astrocytic functions during brain activation, in fact glycogen is located mainly in 
astrocytes and widely distributed throughout brain, and glycogen phosphorylase is 
present in the soma, end-feet and fine processes (Dienel et al., 2006). Glycogen 
levels change during stress conditions: during physiological stimulation the rate of 
glycogenolysis in brain rises 50-fold above that in the resting state, whereas it 
increases more than 200-fold during an energy crisis when oxygen or glucose supply 
is inadequate or eliminated (Magistretti, 1993). 
Neurons are more sensitive to ATP depletion than astrocytes. In fact astrocytes, 
but not neurons, are capable of storing glycogen and glycogenolysis is another 
mechanism by which astrocytes can resist ischemia-like conditions (Parkinson and 
Xiong, 2004). Glycogenolysis produces glucose-6-P but the metabolic fate of this 
compound derived from glycogen in vivo is not well known, moreover the activity 
glucose-6-phosphatase which produces glucose from glucose-6-P in brain and 
cultured astrocytes is very low and therefore, the glycogen metabolism generates 
lactate, which is released to the tissue culture medium (Dienel et al., 2006). On the 
contrary, the plasma lactate cannot fully substitute for glucose as a metabolic 
substrate for brain because of its limited permeability across the blood-brain barrier 
(Dienel et al., 2006). 
In response to an acute hypoxic challenge, astrocytes respond to hypoxia by 
mobilizing their glycogen stores and by increasing their glucose utilization and 
lactate release for their own survival as well as for the neighbouring cells. In fact in 
the astrocyte cells, during hypoxia, there is an enhancement of the expression of the 
sodium-dependent and independent glucose transporters and also of the astrocytic 
monocarboxylate transporters isoform MCT1 (Vega et al., 2006; Brown et al., 2007). 
Astrocyte glycogen, therefore, offers some protection against hypoglycemic 
neural injury and ensures that neurons and axons can maintain their function during 
very intense periods of activation. These emerging principles about the roles of 
astrocyte glycogen contradict the long held belief that this metabolic pool has little or 
no functional significance (Brown et al., 2007). After a prolonged hypoxia exposure, 
astrocytes decrease their glucose uptake and the lactate release, conserving lactate to 
ensure their own survival to the detriment of surrounding cells that could use the 
released lactate as a source of energy (Vega et al., 2006). These findings could 
explain the higher susceptibility of neurons to hypoxia and their earlier cell death 
compared with astrocytes when exposed to long-term hypoxic challenges (Vega et 
al., 2006). 
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2.4 Lactate 
 
Lactic acid is a chemical compound that plays a role in several biochemical 
processes. In animals, L-lactate is constantly produced from pyruvate via the enzyme 
lactate dehydrogenase (LDH) in a process of fermentation during normal metabolism 
and exercise. A number of recent observations have challenged the canonical view of 
glucose as the sole energy substrate delivered directly to neurons via the blood 
supply to sustain their activity: many lines of evidence reveal that monocarboxylates, 
and in particular lactate, might play useful roles in the adult central nervous system 
(Parkinson and Xiong, 2004). 
Neurons, astrocytes, and oligodendrocytes use lactate as a preferential substrate 
for both energy purposes and as precursor of lipids (Parkinson and Xiong, 2004). 
Astrocytes use lactate and other metabolic substrates for the synthesis of oleic acid a 
fatty acid which is able to increase the fluidity of the neurite bases suggesting that 
increased fluidity is required at the sites of newly emerging axons and dendrites. 
Oligodendrocytes mainly use lactate as precursor of lipids, presumably those used to 
synthesize myelin. Neurons use lactate as a source of energy and as precursor of 
lipids (Smith et al., 2003).  
Lactate produced by muscle during strenuous exercise could be used as a fuel 
source by the brain (Smith D. et al., 2003). During the perinatal period, neurons may 
use blood lactate directly to meet the need for the energy and carbon skeletons 
required for proliferation and differentiation (Medina and Tabernero, 2005). Lactate 
is a hydrophilic compound which requires transporters to cross cellular membranes. 
A family of proton-linked monocarboxylate transporters has been described. It 
contains 14 members sharing sequence homologies and identified as MCT1 to 9 and 
MCT11 to 14 as well as another member known as TAT1.  
A distribution of specific MCTs between different cell types is consistent with a 
role in mediating a transfer of energy substrates from astrocytes to neurons. It is also 
correlated with a differential distribution of lactate dehydrogenase (LDH) isoforms: 
LDH1 appears to be the predominant isoform in neurons, whereas LDH5 is found 
predominantly in astrocytes (Laughton et al., 2000). 
Lactate dehydrogenase is the enzyme catalysing the interconversion of pyruvate 
and lactate, and is thus essential for both production and utilization of lactate. It is a 
tetrameric enzyme which can consist of three types of subunit arising from three 
distinct genes: LDH-A, LDH-B and LDH-C The product of the LDH-C gene is 
found exclusively in the testis, where it forms a homogeneous tetramer (C4). The 
LDH-A and LDH-B gene products are more widely expressed, and both are found in 
the CNS (Laughton et al., 2000; Medina and Tabernero, 2005).  
Hypoxia is the oxygen deprivation which provokes a mitochondrial dysfunction 
and a diminution in the levels of the intracellular energy metabolites which leads to a 
drastic reduction of ATP production with a concomitant neurodegeneration through 
both apoptotic and necrotic mechanisms (Cater et al., 2003). In terms of energy 
metabolism, during hypoxia, there is a rapid switch from oxidative phosphorylation 
to anaerobic glycolysis, in order to maintain the cellular energy charge. Under 
normal physiological conditions the NAD+ molecules necessary to drive the 
glycolytic reactions are regenerated via the TCA cycle.  
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During anaerobic conditions, the TCA cycle cannot operate in the absence of 
oxygen so an alternative source of NAD+ is provided through the conversion of 
pyruvate, derived from glucose, to lactate (Cater et al., 2003).  
Therefore, during oxygen deprivation in nervous tissue, a significant rise of the 
lactate concentrations is observed which could lead to acidosis and for this reason, 
lactate for a long period was considered the major factor in the resultant neuronal 
degeneration (Cater et al., 2003). The amount of acidosis differs between animal 
models, yet intracellular pH typically acidifies to the range of pH 6.5–6.7 (Cater et 
al., 2003). 
A research in vitro suggests that the role of lactate during neuronal stress may, on 
the contrary, be beneficial under certain circumstances (Cater et al., 2003). There are 
also some lines of evidence in vivo that lactate is neuroprotective in a number of 
ischemic/excitotoxic models as well as following severe insulin-induced 
hypoglycemia (Schurr et al., 2001). 
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3 Biochemistry of the purine and pyrimidine nucleotide compounds 
 
3.1 General aspects 
 
A nucleotide is a chemical compound that consists of a heterocyclic base, a sugar, 
and one or more phosphate groups. In the most common nucleotides the base is a 
derivative of purine or pyrimidine, and the sugar is the pentose (five-carbon sugar) 
deoxyribose or ribose. All types of cells (mammalian, bacterial and plant) contain a 
wide variety of nucleotides and their derivatives. In normal cells the total 
concentrations of the nucleotides are fixed within rather narrow limits, although the 
concentration of the individual components can vary. The total concentration of 
adenine nucleotides (AMP, ADP and ATP) is constant, although there is a variation 
in the ratio of ATP to AMP+ADP, depending on the energy state of the cells. 
Deoxyribonucleotides are formed by the direct reduction of the 2’ position of the 
corresponding ribonucleotides. This reaction occurs at the level of the nucleoside 
diphosphates and is catalyzed by nucleoside diphosphate reductase. It is generally 
accepted that only liver and kidney maintain the de novo pyrimidine and purine 
synthesis and supply other tissues and organs, including brain, with preformed 
pyrimidine nucleosides and purine nucleosides and bases. 
In the central nervous system, most of the enzymes involved in the purine 
nucleotide metabolism (except for the de novo pathway and of AMP-5'-
nucleotidase), exhibits a higher activity in the astroglia, in comparison to the 
neurons. Thus, as for other metabolic pathways, the glia appears to be more active 
than the neurons (Zoref-Shani, et al., 1995). 
The functions exerted by nucleotides are:  
1. role in energy metabolism: ATP is the main form of chemical energy available to 
the cell and is generated by oxidative phosphorylation and substrate-level 
phosphorylation. The ATP is utilized to drive metabolic reactions as a 
phosphorylating agent and is involved in several processes as muscle contraction, 
active transport and maintenance of cell membrane integrity. ATP donates the 
phosphate also for the generation of the other nucleoside 5’-triphosphates (GTP, 
UTP and CTP). GTP is considered an important non-protein organic cofactor and 
enzyme regulator present in all cells. GTP produces energy for the assemblage of 
ribosome, kinesins and myosines.  
2. monomeric units of nucleic acids DNA and RNA. 
3. mediators of key metabolic processes. (es. cyclicAMP, involved in the molecular 
signal evoked by hormones) 
4. components of coenzymes (NAD, NADP, FAD and CoA) which are involved in 
many metabolic pathways. 
5. allosteric effectors; in fact, many of the regulated steps of the metabolic pathways 
are controlled by the intracellular concentrations of nucleotides. 
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3.2 Metabolic pathways of purines and pyrimidines  
 
3.2.1 De novo purine synthesis 
 
Purine nucleotides may be formed de novo, from small molecules, or by salvage, 
from preformed purines. The former pathway is associated mainly with cell 
proliferation, requiring formation of new nucleic acids, whereas the latter pathway is 
associated with maintenance of cellular purine pool size (Zoref-Shani et al., 1995). 
The de novo synthesis of purine nucleotides in which these precursors are 
incorporated into the purine ring, proceeds by a 10 step pathway to the final point 
intermediate IMP, the nucleotide of the base hypoxanthine and AMP and GMP are 
subsequently synthesized from this intermediate via separate, two step each, 
pathways. Thus purine moieties are initially formed as part of the ribonucleotides 
rather than as free bases. The basal precursor for the de novo synthesis of purine (and 
pyrimidine) is 5-phosphoribosyl-1-pyrohosphate (PRPP). PRPP is formed by ribose 
5-phosphate and ATP by a reaction catalyzed by PRPP synthetase.  
The purine ring atoms is built using a variety of different precursors: N1 of 
purines arises from the amine group of aspartate; C2 and C8 originate from N10-
formyltetrafolate; N3 and N9 are contributed by the amide group of glutamine; C4, 
C5 and N7 are derived from glycine; C6 comes from HCO3- (CO2). The de novo 
synthesis requires directly four ATP molecules.               
In the whole brain, there is a maturation-dependent decrease in the capacity to 
produce purines de novo, and this particular trend reflects the trend observed in the 
astroglia, rather than that in the neurons (Zoref-Shani et al., 1995). 
 
3.2.2 Purine catabolism 
The end product of purine catabolism in man is uric acid. Other mammals have 
the enzyme urate oxidase and excrete the more soluble allantoin as the end product. 
Man does not have this enzyme so urate is the end product. Uric acid is formed 
primarily in the liver and excreted by the kidney into the urine (Fig.3).  
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Fig.3 Schematic illustration of purine catabolism (Image taken from  
web.virginia.edu) 
 
Nucleotides are hydrolyzed to nucleosides by the enzyme family of 5’-
nucleotidase (5NT) which have a different subcellular location and a remarkable low 
sequence homology; 5’-nucleotidases hydrolyze the phosphate esterified at the 5’ 
position of purine and pyrimidine nucleoside monophosphates (Allegrini et al., 1997, 
2004; Pesi et al., 2004).  
ATP degradation proceeds via AMP, which can be either dephosphorylated to 
adenosine, catalyzed by AMP-5'-nucleotidase, or deaminated to IMP, catalyzed by 
the enzyme adenylate (AMP) deaminase. The reaction catalyzed by AMP deaminase 
is the rate-limiting step in the operation of the purine nucleotide cycle (AMP →IMP 
→ adenylosuccinic acid →AMP). This cycle has a major role in the maintenance of 
the normal energy charge in the cell, as well as in the preservation of cellular purine 
nucleotide content. Guanine nucleotides are hydrolyzed to the nucleoside guanosine 
which undergoes phosphorolysis to guanine and ribose 1-P.  
Rather, AMP is deaminated by the enzyme AMP deaminase to IMP. AMP 
deaminase is activated by K+ and ATP and is inhibited by Pi, GDP and GTP.  
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In the catabolism of purine nucleotides, IMP is further degraded by hydrolysis 
with nucleotidase to inosine and then phosphorolysis to hypoxanthine in a reaction 
catalyzed by purine nucleoside phosphorylase (PNP), which acts also on guanosine 
and xanthosine in order to produce guanine and xanthine and Rib1-P. Based on their 
structural properties, nucleoside phosphorylases have been classified into two 
families: NP-I and NP-II. The NP-I family includes homotrimeric and 
homohexameric enzymes from both prokaryotes and eukaryotes acting on inosine, 
guanosine, adenosine and uridine. The NP-II family includes homodimeric proteins 
structurally unrelated to the NP-I family, such as bacterial pyrimidine phosphorylases 
and eukaryotic thymidine phosphorylase (Tozzi et al., 2006). It has been shown that 
the activity of purified PNP from bovine spleen may be inhibited by the 
accumulation of its metabolic products (hypoxanthine and guanine), but it is also 
inhibited by a negative control exerted by the respective substrates, inosine and 
guanosine, especially when their concentrations are elevated, to the micromolar 
range (Tozzi et al., 2006). 
The equilibrium of PNP-catalysed reactions is thermodynamically in favour of 
nucleoside synthesis. Nevertheless, in vivo the equilibrium of the PNP reaction is 
shifted towards Rib-1-P accumulation because the intracellular concentration of Pi is 
higher than that of nucleosides inosine and guanosine and also because hypoxanthine 
and guanine are consumed by hypoxanthine-guanine phosphoribosyltransferase 
(HPRT) and, in certain tissues, by xanthine oxidase or guanase, respectively (Tozzi 
et al., 2006). The phosphorolysis of inosine and guanosine is favoured also because 
mammals lack the kinase acting on inosine and guanosine (Tozzi et al., 2006). PNP 
is generally considered as an intracellular enzyme. In fact, the presence of this 
enzyme is not demonstrated extracellularly (Tozzi et al., 2006).  
Adenosine is deaminated to inosine by an adenosine deaminase. Both adenine and 
guanine nucleotides converge at the common intermediate xanthine. Hypoxanthine is 
oxidized to xanthine by the enzyme xanthine oxidase. Guanine is deaminated, with 
the amino group released as ammonia, to xanthine. Xanthine, like hypoxanthine, is 
oxidized by oxygen and xanthine oxidase with the production of hydrogen peroxide. 
In man, the urate is excreted and the hydrogen peroxide is degraded by catalase. 
Xanthine oxidase is present in significant concentration only in liver and intestine. 
The pathway to the nucleosides, possibly to the free bases, is present in many tissues. 
The key enzyme for the catabolism of the pentose moiety of deoxyribonucleosides is 
deoxyriboaldolase, which cleaves deoxyRib-5-P into acetaldehyde and 
glyceraldehyde 3-P.  
 
3.2.3 Purine salvage 
 
Whereas some organs such as kidney and liver or some cell types such as 
hepatocytes can synthesize purine and pyrimidine nucleotides de novo, others, in 
particular protozoan parasites and cells in the brain and bone marrow, rely on salvage 
pathways for purine and pyrimidine nucleotide synthesis (King et al., 2006). In the 
cultured astroglia, de novo purine synthesis is found to decrease with aging, but the 
activity of the salvage enzyme HGPRT, is found to increase (Zoref-Shani et al., 
1995).  
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In contrast to the glia, in the cultured neurons, the rate of de novo purine synthesis 
is found to increase with maturation (Zoref-Shani et al., 1995). The finding of the 
age-related increase in the rate of de novo purine synthesis in the non-dividing 
neurons, may be interpreted to indicate that the functioning mature neurons, more 
than the glia, have to cope with loss of purines from the cells (Zoref-Shani et al., 
1995). 
The de novo synthesis of purine and pyrimidine requires a relatively high input of 
energy in the form of ATP. To compensate for this, most cells have developed a very 
efficient salvage pathway, by which the preformed purine and pyrimidine bases can 
be reutilized and so, the cell obtains a considerable energy saving for itself. The 
synthesis of nucleotides from the purine bases and purine nucleosides takes place in a 
series of steps known as the salvage pathways. The free purine bases, adenine, 
guanine, and hypoxanthine, can be reconverted to their corresponding nucleotides by 
phosphoribosylation. Two key transferase enzymes are involved in the salvage of 
purines: adenosine phosphoribosyltransferase (APRT), which catalyzes the following 
reaction:  
adenine + PRPP ↔AMP + PPi  
and hypoxanthine-guanine phosphoribosyltransferase (HGPRT), which catalyzes the 
following reactions:  
hypoxanthine + PRPP ↔IMP + PPi  and guanine + PRPP ↔ GMP + PPi;  
these reactions are important not only because they conserve energy, but also 
because they permit cell such as erythrocytes, neurons and astrocytes (which do not 
possess the de novo purine synthesis) to form nucleotides from the bases. AMP is an 
inhibitor of APRT and IMP and GMP regulates the HGPRT activity. 
PRPP may be considered as a high-energy sugar phosphate, with a high potential 
of 5-phosphoribosyl transfer; PRPP is also the common precursor of both de novo 
and salvage synthesis of nucleotides. During physiological cell conditions, the PRPP 
pool is maintained at low level, to avoid excessive and unbalanced nucleotide 
synthesis. PRPP level is regulated by PRPP synthetase and by phosphoribosyl 
transferases which are the major factors maintaining the low intracellular level of 
PRPP. PRPP level is also regulated by the inosine nucleoside cycle (INC) constituted 
by HGPRT (which forms IMP from hypoxanthine), PNP (which forms inosine from 
hypoxanthine and vice versa) and cN-II (which forms inosine from IMP). Some 
experiments exerted in rat brain extracts reveal that when PRPP is present, the 
intermediates of the INC are continuously recycled but as soon as PRPP disappears, 
HGPRT becomes inactive and the cycle is interrupted causing IMP degradation by 
cN-II, and hypoxanthine accumulation. The [Pi]/[ATP] ratio regulates the inosine 
cell cycle and the PRPP levels: in fact, the allosteric activators of cN-II are 2,3-
bisphosphoglycerate (BPG),and ATP while Pi is an inhibitor of the enzyme and at 
the normal low [Pi]/[ATP] ratio, as found in  the well-oxygenated cells, cN-II is fully 
active and the velocity of the cycle is maximal and the PRPP pool is maintained at a 
low level (Barsotti et al., 2002). On the other hand, during ischemia the [Pi]/[ATP] 
ratio raises drastically and cN-II is inhibited while PRPP synthetase is activated: as 
consequence the PRPP level increases and PRPP is made available for purine 
nucleotide salvage synthesis (Barsotti et al., 2002). 
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3.2.4 De novo pyrimidine synthesis 
The pyrimidine ring is synthesized de novo in mammalian cells utilizing amino 
acids as carbon and nitrogen donors and CO2 as a carbon donor. In particular the N1, 
C4 and C6 of the pyrimidine ring derive from aspartate, while the N3 from glutamine 
and C2 from CO2. As is true with purine nucleotides, the sugar phosphate portion of 
the molecule is supplied by PRPP. Pyrimidine synthesis begins with carbamoyl 
phosphate II (CPII) synthesized in the cytosol of those tissues capable of making 
pyrimidines (highest in spleen, thymus and testes). Carbamoyl phosphate condenses 
with aspartate in the presence of aspartate carbamoyl transferase to yield N-
carbamylaspartate which is then converted to dihydroorotate by dihydroorotase and 
subsequently, oxidated into orotate by dihydroorotate dehydrogenase. Orotate is 
converted to its nucleotide, orotidine 5’-monophosphate (OMP) with PRPP, which is 
the ribose-5-phosphate donor. This reaction is catalyzed by orotate 
phosphoribosyltransferase. In the last step pathway, OMP is decarboxylated into 
UMP by OMP-decarboxylase. After conversion of UMP to the triphosphate, the 
amide of glutamine is added, at the expense of ATP, to form CTP by CTP 
synthetase. The de novo synthesis of purine differs by the de novo synthesis of 
pyrimidine in two major respects. First, in purine nucleotide synthesis, the N-
glycosidic bond is formed in the first committed step of the pathway. In the 
pyrimidine pathway, the first step is the formation of the ring and then the phosphate 
is added. Second, all the enzymes of the purine nucleotide pathway are in the cytosol, 
while in the case of the pyrimidine synthesis, the enzyme dihydroorotate 
dehydrogenase is localized in the mitochondria.  
 
3.2.5 Pyrimidine catabolism 
In contrast to purines, pyrimidines undergo ring cleavage and the usual end 
products of catabolism are β amino acids plus ammonia and carbon dioxide. 
Pyrimidines from nucleic acids or the energy pool are acted upon by nucleotidases 
and pyrimidine nucleoside phosphorylase to generate the free bases. Cytidine and 
deoxycytidine are deaminated to uridine and deoxyuridine, by the nucleoside 
deaminase. Uridine phosphorylase catalyzes the phosphorolysis of uridine, 
deoxyuridine and deoxythimidine. As already described, the equilibrium of the 
reaction catalyzed by PNP is shifted towards Rib-1-P accumulation even if the 
reaction is thermodynamically in favour of nucleoside synthesis. On the other hand, 
some in vitro experiments reveal that uridine phosphorylase may catalyse the Rib-1-
P-mediated rybosilation of 5-fluorouracil and uracil, even in the presence of excess 
of Pi (Mascia et al., 1999, 2001). Uridine phosphorylase plays an important role in 
the homeostatic regulation of uridine concentration in plasma and tissues (Pizzorno 
et al., 2002). 
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3.2.6 Pyrimidine salvage 
 
Pyrimidine nucleotide salvage is important for the synthesis of RNA and DNA. 
Moreover, salvage pyrimidine synthesis is used also for phosphatidylcholine and 
phosphatidylinositol synthesis in lymphoid cells. In particular, in CNS the continued 
biosynthesis of phospholipids needs specific activated pyrimidine nucleotides. Even 
the conversion of uracil to L-alanine is important in neuronal cells since L-alanine, 
which is produced and exported by liver, enters the CNS and may act as a 
neurotransmitter, as well as a building block for various dipeptides (Mascia et al., 
1999). 
A crucial difference between purine and pyrimidine metabolism is that purines are 
recycled from their bases while pyrimidines are salvaged from their nucleosides, 
particularly uridine. In fact, in patients with deficient pyrimidine biosynthesis, only 
uridine is able to overcome this pathological manifestation but uracil is not (Pizzorno 
et al., 2002). 
Uracil can be salvaged to form UMP through the concerted action of uridine 
phosphorylase and uridine kinase, as indicated:  
uracil + ribose-1-phosphate  ↔ uridine + Pi  
uridine + ATP → UMP + ADP  
uridine phosphorylase type 1 (UPase-1) activity has been reported in the 
homogenates of many human tissues and from tumours. However, several studies 
reveal that that functional UPase-1 is confined predominantly to the liver in humans 
(Loffler et al., 2005). A second minor human uridine phosphorylase, UPase-2 is 
identified recently, and is expressed predominantly in the kidney (Loffler et al., 
2005). Deoxyuridine is also a substrate for uridine phosphorylase. The salvage of 
dTMP requires thymine phosphorylase and the previously encountered thymidine 
kinase:  
thymine + deoxyribose-1-phosphate ↔ thymidine + Pi  
thymidine + ATP → dTMP + ADP  
The salvage of deoxycytidine is catalyzed by deoxycytidine kinase 
deoxycytidine + ATP ↔ dCMP + ADP 
Intracellularly, mitochondrial and cytosolic nucleoside kinases participate in the 
recycling of uridine, deoxycytidine and deoxythymidine arising from cell turnover or 
diet, thereby restricting the requirement for the energetically expensive de novo 
synthesis. Although deoxynucleotides are considered to be used exclusively in DNA 
replication and repair, deoxycytidine is also known to be salvaged as a precursor for 
phospholipid synthesis (Loffler et al., 2005). 
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3.3 Metabolism of the pentose phosphate 
 
Pentose phosphates are heterocyclic, five-membered, oxygen-containing 
phosphorylated ring structures, with ribose-5-phosphate and 2-deoxyribose-5-
phosphate being basal structures of ribonucleotides and deoxyribonucleotides, 
respectively, and 5-phosphoribosyl-1-pyrophosphate (PRPP). There are two 
pathways of the pentose phosphate biosynthesis (Fig.4): the pentose phosphate 
pathway where Rib-5-P is generated from glucose-6-phosphate and the 
phosphorylase-mediated pathway where Rib-1-P and deoxRib-1-P are supplied by 
various nucleoside phosphorylases, such as thymidine phosphorylase, uridine 
phosphorylase and purine nucleoside phosphorylase. Rib-5-P can be also formed 
from free ribose by the action of ribokinase an enzyme well characterized in bacteria 
but less investigated in mammals. Phosphopentomutase catalyzes the reversible 
reaction between Rib-1-P and Rib-5-P and between deoxyRib-1-P and deoxyRib-5-
P. This enzyme has been extensively studied in bacteria but has been purified also in 
human cell lines and tissues. The key enzyme for the catabolism of the pentose 
moiety of deoxyribonucleosides is deoxyriboaldolase, which cleaves deoxyRib-5-P 
into acetaldehyde and glyceraldehydes 3-P.  
 
 
Fig.4 Pathways of the pentose phosphate biosynthesis. 
 
Some experiments performed in rat brain extracts show that the activated ribose, 
originating from inosine and guanosine phosphorolysis as ribose 1- phosphate, can 
be transferred to uracil to synthesize uridine by uridine phosphorylase and the 
nucleoside formed is phosphorylated to UMP by uridine kinase, and hence to UDP 
and UTP (and possibly to CTP). The transfer of the ribose moiety occurs even in the 
presence of excess Pi, suggesting that at least in brain, uridine phosphorylase might 
function in vivo as an anabolic enzyme (Mascia et al., 1999). CTP and UTP, the final 
products of the pyrimidine salvage, inhibit their production and this inhibition occurs 
at the level of uridine kinase, the enzyme which regulates the flux (Mascia et al., 
1999). The absence of any PRPP involvement in this metabolic pathway, is 
supported by the lack of uracil phosphoribosyltransferase activity.  
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The rate of this pyrimidine salvage pathway is about threefold higher in brain than 
in liver, possibly reflecting the need of CNS to synthesize pyrimidine nucleoside 
diphosphate sugars for myelin biosynthesis (Mascia et al., 1999). The transfer of the 
ribose moiety stemming from the purine nucleoside to the uracil via uridine 
phosphorylase in order to produce uridine and then UMP, UDP and UTP, is also 
demonstrated in liver and PC12 cells (Mascia et al., 2001). In addition, the ribose 1-P 
stemming from the purine nucleoside is also able to enter the purine salvage pathway 
and then produce the purine nucleotide compounds: the pentose phosphate is 
isomerized into ribose 5-P and then converted to PRPP by PRPP synthetase and 
PRPP can react with adenine, guanine and hypoxanthine in order to form AMP, 
GMP and IMP respectively through the action of APRT and HGPRT (Tozzi et al., 
2006). On the other hand, deoxyRib-5-P is not a substrate of PRPP synthetase and 
then the pentose phosphate stemming from the purine deoxynucleoside is not able to 
enter the purine salvage pathway. Thus the ribose 1-phosphate stemming from the 
purine nucleoside is able to enter also the pyrimidine salvage pathway in order to 
produce the nucleotide compounds establishing a metabolic link between purine and 
pyrimidine salvage (Mascia et al., 1999, 2001; Tozzi et al., 2006).  
Ribose 1-phosphate formed from guanosine through the action of purine nucleoside 
phosphorylase acts as ribose donor also in the synthesis of xanthosine catalyzed by 
the same enzyme (Giorgelli et al., 1997). 
 
3.4 Adenosine metabolism in the central nervous system 
 
Adenosine is an endogenous nucleoside consisting of the purine base, adenine, in 
glycosidic linkage with the sugar ribose. Adenosine is generated in the cells and in 
the extracellular space during normal metabolic activity and can exert its biological 
activity by ligating specific receptors linked to a variety of signalling systems (Hasko 
et al., 2005). In the cells, adenosine is generated from AMP which is 
dephosphorylated by 5’-nucleotidase and from S-adenosylhomocysteine which is 
hydrolyzed into adenosine and homocysteine by S-adenosylhomocysteine hydrolase 
(SAH); the first reaction predominates during metabolically stressful conditions 
while the second predominates in the physiological conditions (Tozzi et al., 2006). 
There are two sources of extracellular adenosine: release of adenosine from the 
intracellular space via specialized bi-directional equilibrative transporters and 
extracellular conversion of released adenine nucleotides (ATP, ADP and AMP) by a 
cascade of ectoenzymes of the ecto-nucleoside triphosphatase (E-NTPase) family 
(Tozzi et al., 2006). E-NTPases include the ecto-ATPase that preferentially 
transforms ATP into ADP; the ecto-ATP diphosphohydrolase, also named 
ectoapyrase, that hydrolyses either ATP or ADP, and the ecto-5’-nucleotidase, GPI-
anchored plasma membrane protein, that catalyses the hydrolysis of nucleoside 5’-
monophosphate to the nucleoside (Tozzi et al., 2006).  
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The ectonucleotidases reduce the amount of ATP available for the activation of P2 
receptors, limiting the excitatory effects of the nucleotide, and, at the same time, 
increase the extracellular levels of adenosine, which is also released per se from 
neurons and glial cells, and may activate A1 and/or A2 receptors (Rathbone et al., 
1999). Therefore ectonucleotidases could play an important role in regulating the 
extent and also the duration of the intracellular signal cascade pathway mediated by 
P1 and P2 receptors (Rathbone et al., 1999). 
The levels of extracellular adenosine also depend on the control of the 
cytoplasmic adenosine concentrations; intracellular levels of adenosine are kept low 
principally by its conversion to AMP by the salvage enzyme adenosine kinase, but 
adenosine may also be degraded to inosine by adenosine deaminase (ADA) (Hasko 
et al., 2005). These enzymes are able to maintain adequate levels of adenosine 
available for nucleic acid and ATP synthesis. The reactions of phosphorylation 
predominate when adenosine occurs at a low physiological concentration (< 1 µM), 
whereas adenosine deaminase is activated at higher concentrations of the substrate (> 
10 µM) during ATP depletion (Borowiec et al., 2006). ADA is mainly a cytosolic 
enzyme, thought to maintain a strict control of adenosine levels, preventing cytotoxic 
actions of adenosine and deoxyadenosine in peripheral tissues and CNS.  
In the central nervous system, ADA activity is most prominent in glia, where its 
activity is at least five times that in peripheral ciliary ganglion neurons and nine-fold 
that in central neurons (Rathbone et al.,1999). ADA is also expressed in the external 
surface of the cells in the CNS. In particular, ADA has been found in the synaptic 
vesicles which contains also ecto-5’-nucleotidase and the combined effect of ecto-5’-
nucleotidase, nucleoside transport and ADA may serve to regulate the effective local 
concentration of adenosine and therefore the extent of adenosine receptor activation 
(Rathbone et al., 1999).  
In the central nervous system adenosine is present at low concentrations in the 
extracellular space and its levels are greatly increased under metabolically stressful 
conditions (Hasko et al., 2005). Under these conditions, the extracellular 
concentration of adenosine rapidly rises from nanomolar to micromolar levels (van 
Calker and Biber, 2005). When adenosine deriving from the intracellular degradation 
of ATP to adenosine by the metabolic enzyme 5’-nucleotidase, reaches high 
concentrations inside the neuronal cell, it is expelled into the extracellular space by 
bidirectional, equilibrative, nucleoside transporters, meaning that the net transport of 
adenosine either into or out of the cell depends upon the adenosine concentration 
gradient in both sides of the membrane. Inhibition of adenosine transport can, 
therefore, inhibits either adenosine release or adenosine uptake, depending upon the 
intra- and extracellular levels of adenosine (Hasko et al., 2005). On the other hand, 
under ATP-depleting conditions, cultured astrocytes first release adenine nucleotides 
which are subsequently hydrolyzed to adenosine extracellularly by ecto-
nucleotidases (Parkinson and Xiong, 2004). 
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3.5 Inosine and guanosine-based purine metabolism in the central 
nervous system 
 
Also in CNS, inosine which derives from the deamination of adenosine, is 
phosphorolytically cleaved by a family of enzymes, the purine nucleoside 
phosphorylases (PNPs), in order to produce the base, hypoxanthine and the 
phosphorylated sugar. The base can be reconverted to IMP by phosphoribosylation 
and the activity of this nucleotide cycle, considered as the main salvage pathway of 
nucleoside, is demonstrated in the brain and dominates in neurons (Tozzi et al., 
2006). 
The pathway for the degradation of IMP proceeds through inosine, hypoxanthine 
and xanthine to uric acid. These reactions are catalyzed by IMP-5'-nucleotidase, PNP 
and xanthine oxidase, respectively. Xanthine oxidase activity could not be detected 
in the cultured astroglia. Absence of xanthine oxidase activity is an advantage for the 
reutilization of hypoxanthine for IMP synthesis (Zoref-Shani et al., 1995).  
Inosine is degraded further to the stable end-product uric acid, which has anti-
inflammatory properties and, as such, is a potential candidate agent for the treatment 
of multiple sclerosis (Mattle H.P. et al., 2004).  
Guanine in the brain is formed by degradation of guanine nucleotides through the 
pathway: GMP → guanosine → guanine.  
Guanine can be reconverted into GMP in the reaction catalyzed by HGPRT, or 
converted to xanthine in the reaction catalyzed by guanase; thus, the fate of guanine 
is determined by the relative activities of these enzymes, since the affinity of both 
enzymes for guanine is apparently similar (Zoref-Shani et al., 1995). In the 45-day-
old rat astroglia, the activity of guanase is four to five-fold that of HGPRT. This ratio 
indicates increased advantage for guanine degradation in the form of xanthine, over 
its reutilization for nucleotide synthesis. A similar situation occurs also in the 
neurons (Zoref-Shani et al., 1995). However, in cultured astrocytes the activity of 
phosphoribosyltransferases and guanase increased markedly with age; thus, cultured 
astroglia are able to metabolise guanine more intensively than are neurons. Guanase 
is considered one of the major responsible for ammonia production in the brain 
(Tozzi et al., 2006). Cells, including astrocytes, cannot accumulate deoxy purines, as 
they are toxic (Tozzi et al., 2006). 
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3.6 Pyrimidine metabolism in the central nervous system 
 
The circulating pyrimidines uridine and cytidine, besides being incorporated into 
nucleic acids, can serve as substrates for the salvage pathway of pyrimidine 
nucleotide synthesis (Cansev et al., 2006). 
Uridine and cytidine are also considered as precursors of the cytidine triphosphate 
(CTP) needed in the phosphatidylcholine (PC) and phosphatidylethanolamine (PE) 
biosynthetic pathway which are the two major membrane phospholipids and they are 
precursors for the UDP and UTP that activate brain P2Y receptors and that promote 
brain glycogen synthesis via UDPglucose (Cansev et al., 2006). Some experiments 
reveal that an increase in neuronal cytidine and uridine levels augments CTP levels 
both in vitro and in vivo. In humans, the predominant circulating pyrimidine is 
uridine whereas in rats, it is cytidine. These variations probably reflect the species 
differences in cytidine deaminase, the enzyme that converts cytidine to uridine in the 
body (Cansev et al., 2006). 
Except for erythrocytes, liver and kidney, which maintain de novo pyrimidine 
biosynthesis and supply other tissues with uridine or cytidine for salvage, in humans 
most normal tissues in adults rely on the salvage of uridine and cytidine (Cao et al., 
2005). The homeostasis of uridine, which regulates several physiological and 
pathological processes, is maintained by the relative activities of two enzymes: the 
UTP-CTP inhibited uridine kinase and uridine phosphorylase. The first produces the 
uridilic nucleotide compounds by the nucleoside uridine whereas the second 
catalyzes the Rib-1-P-mediated ribosylation of uracil in order to produce the 
nucleoside (Tozzi et al., 2006).  
As already described, the reaction catalyzed by uridine phosphorylase acts 
anabolically and at least in rat brain, the anabolism of uridine mediated by the uridine 
phosphorylase enzyme, is favoured because the degradation of uracil to β-alanine, 
which would drive uridine phosphorolysis, is absent and also because multiple 
consecutive phosphorylations of uridine by the ubiquitous uridine kinase and 
nucleoside mono and diphosphokinases drive the phosphoribosylation of uracil 
catalysed by uridine phosphorylase. Moreover, the absence of uracil 
phosphoribosyltransferase (catalyzing the formation of UMP by uracil and PRPP) in 
mammals, further leads to the uracil phosphoribosylation (Tozzi et al., 2006). 
In rat brain, de novo pyrimidine synthesis, although at lower rates than those of 
liver, has been described and brain pyrimidine levels depend on de novo synthesis 
even if circulating cytidine and uridine are essential for maintaining various brain 
functions. Thus, pyrimidines have to be taken up from the circulation in order to 
maintain all brain functions. Hence, their plasma concentrations, as well as their 
transport proteins, will be important in modulating brain levels of cytidine and 
uridine (Cansev et al., 2006).  
The liver has been proposed as the major tissue for regulating plasma pyrimidine 
levels even if, in humans, the liver may not be the major catabolic tissue for 
pyrimidines; there may be multiple sites of uptake and degradation such as in 
erythrocytes (Cansev et al., 2006). 
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4. Neurological disorders in purine and pyrimidine dismetabolism 
 
Neurological disorders are disorders that affect the central nervous system (brain 
and spinal cord), the peripheral nervous system (peripheral nerves and cranial nerves 
included), or the autonomic nervous system. It is well established that there is a 
strong correlation between the alteration of purine and pyrimidine metabolism and 
the outbreak of neurological disorders. In particular, deficiencies of some enzymes of 
purine and pyrimidine metabolism have been known to be associated with severe 
neurological dysfunctions.  
 
4.1 Alteration of purine metabolism 
 
Lesch-Nyhan syndrome (LNS) is caused by the complete deficiency of the 
enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT). In the absence 
of HGPRT, hypoxanthine and guanine are not utilized but are degraded to uric acid 
which is overproduced. Besides the absence of the recycling of purine bases there is 
a pronounced activation of purine synthesis via de novo pathway (Nyhan et al., 
2005). In this syndrome, the direct cause for the neurological deficit has been shown 
to be defective arborization of the dopaminergic neurons, but the relationship 
between a complete deficiency of HGPRT and the neurobehavioural abnormalities in 
Lesch-Nyhan disease remains an enigma (Nyhan et al., 2005). These studies reveal 
several metabolic alterations, including excessive production and excretion of uric 
acid, which may be the link between HGPRT deficiency and the derangement in 
dopamine metabolism. The gene of HGPRT is located on the X chromosome and the 
expression is almost exclusively recessive, but a small number of females have been 
reported, most reflecting nonrandom inactivation of the normal X chromosome 
(Nyhan et al., 2005). 
The clinic picture combines neurologic features of retarded motor development, 
dystonia and involuntary movements, and self-injurious behaviour. The patient is 
unable to walk or to sit unassisted. Loss of tissue results from biting of lips or fingers 
or both. Patients are not insensitive to pain. Aggressive behaviour is also directed 
against others. Hyperuricemia causes a deposition of uric acid crystals in the kidneys, 
joints and subcutaneous tissues. These deposits may cause gouty arthritis, tophi, 
hematuria, nephrolithiasis, urinary tract infection, and renal failure (Nyhan et al., 
2005). Treatment with allopurinol, a xanthine oxidase enzyme inhibitor, is useful to 
prevent the hyperuricemia, but has no beneficial effect on the neurobehavioral 
features of the disease. In fibroblasts of patients affected by Lesch-Nyhan syndrome, 
a reduced cytidine/uridine salvage into UDP sugars is observed and the incorporation 
of uridine into CTP is minimal compared to the levels of cytidine metabolized to 
UTP, indicating that fibroblasts, unlike lymphoblasts, lack active CTP synthetase. 
Therefore, Lesch-Nyhan fibroblasts show a disturbed pyrimidine metabolism. Thus, 
aberrant pyrimidine nucleotide metabolism, could play a vital role in the 
pathophysiology of Lesch-Nyhan disease (Fairbanks et al., 2002). 
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The other disorder that causes hyperuricemia results from variation in 
phosphoribosylpyrophosphate (PRPP) synthetase which catalyzes the conversion of 
the ribose5-P into PRPP. This disorder leads to greater than normal enzymatic 
activity. Complications include nephropathy, urinary tract calculi, and gouty arthritis 
(Nyhan et al., 2005). 
Another disorder of purine metabolism that leads to renal stone disease in children 
is adenine phosphoribosyltransferase (APRT) deficiency. This enzyme catalyzes the 
conversion of adenine to its mononucleotide (AMP). Deficiency of APRT leads to 
accumulation of adenine, which is oxidized in the presence of xanthine oxidase to 
2,8-dihydroxyadenine. This compound is very insoluble (Nyhan et al., 2005). 
Adenosine deaminase (ADA) deficiency is the major metabolic cause of severe 
combined immunodeficiency disease (SCID) with mental and growth retardation; 
ADA catalyzes the irreversible deamination of adenosine to form inosine, and of 
deoxyadenosine to deoxyinosine (Nyhan et al., 2005). The ADA-immunodeficiency 
syndrome results in the accumulation of toxic levels of adenosine and 2-deoxy-Ado 
with a failure of embryonic neural cell development (Nyhan et al., 2005). 
Purine nucleoside phosphorylase (PNP) catalyzes the reversible cleavage of 
inosine and guanosine to their respective bases hypoxanthine and guanine. 
Deoxyinosine and deoxyguanosine are also substrates. PNP deficiency causes a 
severe immune-deficiency syndrome associated with incomplete cerebral 
development and mental retardation which is SCID indistinguishable from that of 
ADA deficiency. In the PNP deficiency, the urinary excretion of uric acid is reduced 
(Nyhan et al., 2005). 
A prominent cause of hypouricemia is hereditary xanthinuria which results from 
deficiency of xanthine oxidase which catalyzes the conversion of hypoxanthine to 
xanthine and can further catalyze the oxidation of xanthine to uric acid. The xanthine 
oxidase deficiency causes a xanthine accumulation and this compound is very 
insoluble; so patients are also of risk for the renal complications of calculus 
formation. Crystals of xanthine may also be found in muscle in patients with 
muscular pains or cramps. Also the deficiency of molybdenum which is the xanthine 
oxidase cofactor, causes hypouricemia. It also causes sulfite oxidase deficiency, a 
much more devastating disease (Nyhan et al., 2005). 
AMP deaminase catalyzes the conversion of AMP to IMP and NH3. The 
deficiency of this enzyme causes pain or cramps in muscle following exercise 
(Nyhan et al., 2005). 
Page et al. (1997) describe some unrelated patients in whom developmental delay, 
seizures, ataxia, recurrent infection, speech deficit, and an unusual behavioural 
phenotype are associated with highly elevated activity of a cytosolic 5’-nucleotidase. 
Moreover, also Lesch-Nyhan patients show cytosolic 5'-nucleotidase hyperactivity in 
erythrocytes (Pesi et al., 2000). In the treatment of a form of autism with seizures, 
oral uridine administration has led to improvement in speech, behaviour and 
decreased frequency in seizures but the relationship between the partial recover of 
the patients and the action of uridine remains an enigma (Page  et al.,1997). 
 
 
 
 
 34 
4.2 Alteration of pyrimidine metabolism 
 
In nature there are several inherited disorders affecting pyrimidine metabolism, 
the clinical signs of which often manifest as a serious disruption of normal 
neurological function. Patients with pyrimidine metabolic, or related, disorders, 
which lead to the excessive production of one or more pyrimidines, exhibit various 
neurological manifestations, for example, hereditary orotic aciduria, ornithine 
carbamoyl-transferase and dihydro pyrimidinase deficiencies. Conversely, a reduced 
synthesis of endogenous pyrimidines has been associated with symptoms of 
schizophrenia and maniac depression, and Huntington’s diseases (Connelly et al., 
1996). 
The classic disorder of pyrimidine biosynthesis de novo is orotic aciduria. The 
metabolic defect is in the enzyme uridine-5-monophosphate (UMP) synthase which 
contains in a single protein the activities of two enzymes, phosphoribosyltransferase 
(OPRT) and orotidine-5’-monophosphate (OMP) decarboxylase, which catalyze the 
last two steps of UMP synthesis. Orotic aciduria is a rare disease that is characterized 
by megaloblastic anemia. Crystals of orotic acid have caused urethral and ureteral 
obstructions hematuria and azotemia. Retardation of physical and intellectual 
development may be observed with or without hematologic abnormalities. The 
activities of OMP and OPRT are deficient in erythrocytes, leukocytes, and cultured 
fibroblasts (Nyhan et al., 2005). 
Uridine monophosphate synthase (UMPS) is the enzyme responsible for 
converting orotic acid to uridine monophosphate (UMP), which is an essential 
component of pyrimidine nucleotides. UMPS type-1 deficiency causes orotic 
aciduria, gross crystaluria and occasional ureteric obstruction (Nyhan et al., 2005). 
Uridine monophosphate hydrolase (UMPH) is the first degradative enzyme of the 
pyrimidine salvage cycle and catalyses the specific hydrolysis of the monophosphate 
nucleotides: uridine monophosphate (UMP) and cytidine monophosphate (CMP) to 
pyrimidines (uridine or cytidine) and Pi. Clinically, UMP hydrolase deficiency 
presents as haemolytic anaemia, with reticulocytosis and gross basophilic stippling, 
sometimes associated with learning difficulties, or as anaemia associated with lead 
poisoning (Nyhan et al., 2005). 
CDP-choline phosphotransferase catalyses the last step in the synthesis of 
phosphatidyl choline. A deficiency of this enzyme is proposed as the metabolic basis 
for the selective accumulation of CDP-choline in the erythrocytes of rare patients 
with an unusual form of haemolytic anaemia. In patients with this defect, which 
occurs mainly in children, CDP-choline and CDP-ethanolamine accumulate in 
erythrocytes to a similar degree as in UMPH-1 deficiency. A diagnosis of CDP-
choline phosphotransferase deficiency should be considered when erythrocyte 
screening shows abnormal nucleotide levels but UMPH-1 activity is normal (Nyhan 
et al., 2005). 
Dihydropyrimidine dehydrogenase (DPD) is the initial and rate-limiting step in 
pyrimidine catabolism. DPD is the first of three enzymes catalysing the degradation 
of uracil or thymine to β-alanine or β-aminoisobutyric acid. DPD deficiency shows 
considerable genetic heterogeneity in clinical presentation, such as epilepsy, 
dysmorphic features and mental retardation (Nyhan et al., 2005). 
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Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is an 
autosomal recessive disorder caused by loss-of-function mutations in the gene 
encoding thymidine phosphorylase (TP) which catalyzes the reversible 
phosphorolysis of thymidine to thymine and 2-deoxy-D-ribose 1-phosphate. MNGIE 
is characterized clinically by onset between the second to fifth decades, apoptosis, 
progressive external ophthalmoplegia, gastrointestinal dysmotility, thin body habitus, 
peripheral neuropathy, myopathy, leukoencephalopathy, and lactic acidosis (Nishino 
et al., 1999).  
No defect in uridine phosphorylase, or four of the six synthetic enzymes, has been 
reported, suggesting that such defects are incompatible with life, or that current 
techniques are not sufficiently sensitive to detect these defects (Loffler et al.,2005). 
The study of purine and pyrimidine metabolism and the pharmacologically 
induced inhibition of key enzymes involved in the synthetic pathways provided much 
useful information for new drug design, particularly in the field of antitumor and 
antiviral agents. Similar studies could also enlarge the knowledge of pathophysiology 
of neurological disorders.  
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5. Physiological activity of purine and pyrimidine compounds 
exerted through a receptor dependent mechanism 
 
5.1 General aspects 
 
Purines and pyrimidines are emerging as physiological regulators of a number of 
cellular functions such as cell growth, differentiation, cell death, release of 
hormones, neurotransmitters and cytokines (Fig.5).  
 
Fig.5. Action of purines and pyrimidines on cells in the CNS (Image taken from 
Abbracchio et al., 1998) 
 
Purines and pyrimidines can also both stimulate the progression of cells through 
the cell cycle and inhibit cell growth, simply depending upon their extracellular 
concentrations, the physiological state of target cells and/or the expression of specific 
receptors called P receptors (Abbracchio and Burnstock, 1998). There are two classes 
of purinergic receptors (P receptors), P1 and P2. P1 receptors are mainly activated by 
adenosine while the P2 are activated by ATP, ADP and UTP. The role of 
extracellular purines in intercellular communication is phylogenetically ancient and 
universal in plants and animals. Receptors for extracellular purine nucleosides are 
found on the surface of all higher animal and tissues (Neary et al., 1996). Some of 
these receptors are linked to signalling mechanisms that have been implicated in 
mitogenesis and differentiation, such as Ca2+ influx and mobilization, 
polyphosphoinositide metabolism and protein phosphorylation (Neary et al., 1996). 
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The principal release of nucleosides from glia is non-exocytotic, independent of 
nucleotide release and occurs through bi-directional nucleoside transport systems as 
has been observed in hippocampal slices and in brain synaptosomal preparations 
(Rathbone et al., 1999). It is evident that alterations in the physiology of purinergic 
signalling may result in the development of a variety of pathologies, including 
immune system diseases, infiammation and pain, neurodegenerative disorders and 
osteoporosis (Abbracchio and Burnstock, 1998). 
The intracellular levels of purine nucleotides and nucleosides also determine the 
amount of these substances that can be released by the cells upon appropriate 
stimulation. Thus, the inhibition of some key enzymes of purine metabolism 
dramatically alters both intracellular and extracellular purine levels (Abbracchio and 
Burnstock, 1998). 
Purine and pyrimidine nucleotides and nucleosides act as trophic agents on the 
cells of the nervous system in several ways: they may target glial cells directly, 
inducing functional changes which modulate neuronal differentiation; they may 
stimulate the synthesis and the release of trophic factors from neuronal and non-
neuronal cells; purines may enhance the effects of growth factors on their target 
cells; finally, purines may interact directly with neurons or neuronal precursors, 
eliciting neuritogenesis, biochemical differentiation, the maintenance of existing 
neuritis or enhancing neuronal survival. Purine nucleotides and nucleosides may also 
act as trophic agents through a combination of these actions (Rathbone et al., 1999)  
Neurotrophic factors are molecules that exert a variety of actions stimulating both 
the development and differentiation of neurons and the maintenance of cellular 
integrity; they are required for the survival and development of neurons throughout 
the life cycle of organisms. Generally, neurotrophic factors may be divided into two 
broad classes: neurotrophins and pleiotrophins. Neurotrophins constitute a large 
family of related proteins such as nerve growth factor (NGF), neurotrophins 3 and 4 
(NT3, NT4) or glial-derived neurotrophic factor (GDNF).  
These proteins are growth factors that encourage survival of nervous tissue after a 
brain injury by prohibiting the neuron from initiating apoptosis. Neurotrophins also 
induce differentiation of progenitor cells, to form neurons (Zafra et al., 1992). 
Pleiotrophins or neurite growth-promoting factors 1 (NEGF1) are an important 
developmental cytokine and constitute a family of secreted heparin-binding proteins. 
Cytokines are a group of proteins and peptides that are used in organisms as 
signalling compounds. These chemical signals are similar to hormones and 
neurotransmitters and are used to allow one cell to communicate with another (van 
Calker and Biber, 2005). Cytokines act in order to stimulate and regulate immune 
cell proliferation and differentiation. A number of glial derived cytokines have also 
been described to have neuroprotective properties; IL-1a, IL-1b, IL-6, IL-10, TNF-a, 
TGF-b and the chemokine CCL2 (van Calker and Biber, 2005). 
Some authors report that purines are able to influence the synthesis and release of 
neurotrophins (for example NGF or GDNF), pleiotrophins (for example FGF in 
neurons and astrocytes) and also cytokines. In particular purines (and also 
pyrimidines) released under some pathological conditions, serve as signal that acts in 
concert with polypeptide growth factors to initiate brain repair mechanisms, 
including astrogliosis, activation of microglial cells and regeneration of damaged 
neuronal axons (Abbracchio and Burnstock, 1998; Yamagata et al., 2007).  
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It is also well established that neurotrophic factors are potential candidates for the 
pharmacological treatment of chronic neurological diseases or acute brain injuries; 
unfortunately, pharmacokinetic features such as the poor penetration across the 
blood-brain barrier limit their systemic administration, which also produces 
peripheral side effects. Therefore, purine and pyrimidines and their analogs can be 
used as pharmacological inductor of local production of these trophic factors 
(Ciccarelli et al., 2001). 
 
5.2 Trophic action of adenosine and classification of adenosine receptors 
in the central nervous system 
 
When adenosine is released both in normoxic and pathological conditions, it 
behaves as an extracellular signal molecule influencing synaptic transmission 
without itself being a neurotransmitter. In fact, while ATP may function as a 
neurotransmitter in some brain areas, adenosine is neither stored nor released as a 
classical neurotransmitter since it does not accumulate in synaptic vesicles, being 
released from the cytoplasm into the extracellular space through a nucleoside 
transporter (Ribeiro et al., 2002).  
The subclassification of adenosine receptors is based on the effects which they 
cause over changing cAMP concentration in the cell and their affinity for the ligand  
(Fig.6) (Borowiec et al., 2006). P1 receptors have four subtypes: A1, A2A, A2B, and 
A3, all of which are G protein-coupled receptors; A1 and A3 receptors activate the Gi 
family of G proteins, whereas A2A and A2B receptors activate the Gs family. 
However, other G proteins can also be activated even though the physiological 
significance of this is unknown (Fredhlom et al., 2001). A2A receptors stimulate 
adenyl cyclase activity and therefore induce an increase of intracellular cAMP which 
activates protein kinase A. On the other hand, A1 receptors may lead to inhibition of 
this enzyme. The activation of A1 and A3 receptors provokes the modification of 
phospholipase C activity and/or phosphoinositide turnover (Ribeiro et al., 2002).  
 
 
 
Fig.6 The subclassification of adenosine receptors (Image taken from 
www.aderis.com/science/programs.htm) 
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In the central nervous system, the adenosine A1 receptor is highly expressed in 
brain cortex, cerebellum, hippocampus, and dorsal horn of spinal cord (Ribeiro et al., 
2002). 
In the peripheral and central nervous system, adenosine is able to regulate nerve 
cell activity. Presynaptically, adenosine inhibits, via A1 receptors, the release of 
several neurotransmitters such as acetylcholine, noradrenaline, serotonin, dopamine 
and excitatory amino acid including glutamate (Rathbone et al., 1999; Martin et al., 
2007). Postsynaptically, adenosine, via A1 receptors, causes hyperpolarization of the 
cell membrane, mainly by increasing K+ conductance, by stabilization of the Mg2+ 
blockade of N-methyl D-aspartate (NMDA) receptors and by a reduction of Ca2+-
influx, probably caused by an inhibition of N-type voltage-dependent Ca2+ channels. 
Thus the sum of these pre- and postsynaptic effects leads to decrease of neuronal 
excitability (van Calker and Biber, 2005). The decrease of neuronal excitability is 
particularly important under pathological conditions such as ischemia, when 
excessive stimulation by excitatory amino acids such as glutamate can lead to death 
of neurons (van Calker and Biber, 2005).  
Astrocytes are the main cerebral source of extracellular adenine- and guanine-
based purines and express specific receptors for these substances. Adenine 
nucleotides stimulate both astrocyte proliferation and differentiation whereas adenine 
nucleosides inhibit cell proliferation and induce apoptosis cell death. The best 
characterised P receptors in astrocyte are those for adenine-based purines, belonging 
to both Ado P1 receptors (A1, A2A, A2B and perhaps A3 subtypes) and ATP P2 
receptors (P2Y1, P2Y2 and P2X7 subtypes) (Neary et al., 1996).  
Adenosine acts at high affinity A1 receptors to reduce astrocyte proliferation. 
Stimulation of A1 receptors exerted by adenosine in cultured astrocytes results in 
hyperpolarization of the membrane potential, inhibition of adenylate cyclase and 
potentiation of the effects of metabotropic glutamate receptor-mediated (van Calker 
D. and Biber K., 2005). 
The stimulation of A2A receptor exerted by adenosine in astrocyte cells, inhibits 
the expression of inducible nitric oxide synthase (iNOS), and thus the production of 
nitric oxide (NO). The production of NO by iNOS in the brain seems to contribute to 
the pathophysiology of many CNS diseases, so the inhibition of NO formation by 
adenosine might be an important protective mechanism during inflammatory 
conditions in the brain (Hasko et al., 2005). Antipsychotic drugs, potent dopamine 
receptor antagonists, are commonly used in the treatment of psychotic and affective 
illness. The discovery of antagonistic interactions between A2A adenosine receptors 
(ARs) and D2 dopamine receptors (DRs) in the central nervous system suggests that 
the adenosine system may be involved in the pathogenesis of psychiatric and 
neurological disorders (Martini  et al., 2006). A2B possesses low levels of expression 
in the brain (Fredholm et al., 2001). Stimulation of A2B (and A1) receptors elicits the 
release of the pro-inflammatory cytokine IL-6 from astrocytes (Hasko et al., 2005; 
van Calker and Biber, 2005). Because IL-6 is neuroprotective against hypoxia and 
glutamate neurotoxicity, stimulation of A2B receptors provides a damage-control 
mechanism during CNS injury (Hasko et al., 2005; van Calker and Biber, 2005). 
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Low-affinity A2B adenosine receptors, which are expressed in astrocytes, are 
mainly activated during brain hypoxia and ischaemia, when large amounts of 
adenosine are released and they are able to stimulate adenylate cyclase through Gs 
proteins  (Trincavelli et al., 2004). Cell treatment with tumor necrosis factor alpha 
increases A2B functional response and receptor G protein, without any changes in 
receptor protein and mRNA levels (Trincavelli et al., 2004). Moreover, in the 
presence of TNF-alpha, A2B stimulation in vitro induced the elongation of astrocytic 
processes, a typical morphological hallmark of in vivo reactive astrogliosis 
(Trincavelli et al., 2004). 
 
5.3 Classification and properties of P2 receptors 
 
P2 receptors are classified into P2X and P2Y receptors. P2X-receptors are ligand-
gated ion channels (ionotropic), whereas P2Y-receptors belong to the superfamily of 
G-protein-coupled receptors (metabotropic). 
P2X receptors are a family of cation-permeable ligand gated ion channels that 
open in response to extracellular adenosine 5'-triphosphate (ATP) and neither G-
proteins nor second messenger cascades appear to be directly involved (Rathbone et 
al., 1999). These ligand-gated channels show little selectivity for monovalent cations 
and are permeable to Na+, K+ and Ca2+ (Rathbone et al., 1999). ATP binds to the 
extracellular loop of the P2X receptor, causing a conformational change in the 
structure of the ion channel which results in the opening of the ion-permeable pore. 
This allows cations such as Na+, K+ and Ca2+ to enter the cell, leading to 
depolarization of the cell membrane and the activation of various Ca2+-sensitive 
intracellular processes. At least three ATP molecules are required to activate a P2X 
receptor, suggesting that ATP needs to bind to each of the three subunits in order to 
open the channel pore (Abbracchio and Burnstock, 1998). P2X receptors are 
expressed in cells from a wide variety of animal tissues.  
On presynaptic and postsynaptic nerve terminals throughout the central, 
peripheral and autonomic nervous systems, P2X receptors have been shown to 
modulate synaptic transmission (Abbracchio and Burnstock,1998). Furthermore, 
P2X receptors are able to initiate contraction in cells of the heart muscle, skeletal 
muscle, and various smooth muscle tissues. P2X receptors are also expressed on 
leukocytes, including lymphocytes and macrophages, and are present on blood 
platelets (Abbracchio and Burnstock, 1998). 
P2Y receptors are G protein-coupled receptors that are stimulated by nucleotides 
such as ATP (P2Y2, P2Y11), ADP, UTP (P2Y2, P2Y4), UDP (P2Y6) and UDP-
glucose. To date, 8 P2Y receptors have been cloned in humans: P2Y1, P2Y2, P2Y4, 
P2Y6, P2Y11, P2Y12, P2Y13 and P2Y14. The P2Y receptors are present in almost all 
human tissues where they mediate slow responses through G-proteins that are usually 
coupled to phospholipase C and activate the inositol phosphate cascade and 
subsequently modulate intracellular calcium (Rathbone et al., 1999). These receptors 
are involved in blood platelet aggregation, vasodilatation and neuromodulation and 
the biological effects of P2Y receptor activation depends on how they couple to 
downstream signalling pathways, either via Gi, Gq or Gs G proteins (Rathbone et al., 
1999; von Kugelgen, 2006). 
 
 41 
 
5.4 Trophic effects of inosine and guanosine-based purines and their 
specific receptors 
 
Inosine has been shown to produce inhibitory responses in rat cerebellar Purkinje 
cells, mouse spinal cord neuronal cultures, rat cortical neurons, and pig hippocampal 
slice. Inosine also appears to elicit a rapidly desensitizing excitatory response in 
mouse spinal cord neuronal cultures (Haun et al., 1996). Inosine delays the time to 
contracture, and decreases infarct size in ischemic myocardium (Haun et al., 1996). 
Shen et al. (2005) demonstrate that inosine is able to reduce ischemic brain injury 
in rats; the authors suppose that the effect is not elicited by hypoxanthine and the 
lack of protection by hypoxanthine indicates that inosine-mediated protection is not 
through the production of active metabolite hypoxanthine or ATP in vivo. In this 
study, the authors find that A3 antagonist MRS1191 attenuated inosine-mediated 
protection, suggesting that the activation of A3 receptors contributes to these 
protective effects of inosine in the CNS (Shen et al., 2005). 
Inosine, guanosine and adenosine are able to improve neurite outgrowth and 
viability in cells subjected hypoxic stress through a strong activation of mitogen-
activated protein (MAP) kinases (Tomaselli et al., 2005) 
There are some lines of evidence indicating that guanosine may also act as 
neurotransmitter or neuromodulator. There is no strong evidence that GTP is a 
neurotransmitter or neuromodulator. However, GTP is stored in synaptic vesicles 
with ATP. This indicates that GTP is co-released with ATP during physiological 
nerve activity (Rathbone et al., 1999). 
Indirect evidence indicates that certain neurons release guanosine following 
depolarization and that extracellular guanosine is excitatory to hippocampal neurons 
in slice preparations (Rathbone et al., 1999). GTP is also found to stimulate voltage-
gated Ca2+ channels to increase [Ca2+]i (Rathbone et al.,1999). Guanosine, GTP and 
cGMP, promote neurite outgrowth from PC12 neuronal cells and also from primary 
cultures of hippocampal neurons (Rathbone et al., 1999). The nucleoside transport 
inhibitors nitrobenzylthioinosine and dipyridamole fail to block this neuritogenic 
effect of guanosine, suggesting that this effect is mediated through cell-surface 
purine receptors and not directly through intracellular mechanisms requiring uptake 
(Rathbone et al., 1999). Exogenous guanine nucleotides and nucleosides are very 
active in stimulating the proliferation rate of different types of cells, including 
cultured astrocytes derived either from avian or mammalian brain (Rathbone et al., 
1999). In fact astrocytes have various receptors for adenosine, but the presence of 
putative receptors or specific binding sites also for guanosine or GTP has been 
postulated in astrocytes (Ciccarelli et al., 2001). Astrocytes release guanine 
nucleotides and guanosine in the resting state and this release is greatly increased by 
an anoxic-hypoglycemic insult (Rathbone et al., 1999). 
Guanine-based purines may increase the production of neurotrophins, such as 
NGF and neurotrophin- 3, and pleiotrophins, such as FGF or S100β protein from 
cultured astrocytes (Ciccarelli et al., 2001). Guanosine activates also MAP kinase 
cascade in cultured astrocytes. This cascade is the primary mechanism by which 
NGF can induce differentiation and neurite outgrowth in a neuronal cell line 
(Ciccarelli et al., 2001). 
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5.5 Trophic effects of pyrimidine compounds and their specific receptors 
 
Uridine, a pyrimidine nucleoside, has a variety of roles in physiological states, 
such as the synthesis of DNA, RNA or biomembranes. Besides these, uridine has a 
lot of roles in biological processes, including vascular resistance, spermatogenesis, 
dopaminergic neurotransmission, and sleep-inducing. Uridine appears to be involved 
in the cellular responses in various tissues under ischemic-like conditions. High 
concentration of uridine is released from cold stored liver after reperfusion and is 
present in plasma after infarct. In addition, uridine perfusion restored myocardial 
ATP, glycogen and uridine diphosphoglucose (UDPG) which functions as a key in 
the transformation of glucose to other sugars (Pizzorno et al., 2002; Choi et al., 
2006). 
Uridine and its nucleotides have shown a complex effect in the regulation of 
vascular resistance, producing opposing effects in some tissues, either by acting 
directly on the smooth muscle cells or by stimulating the surrounding endothelial 
cells (Pizzorno et al., 2002). Uridine is also present in the seminal fluid at millimolar 
concentrations, a level that is approximately three orders of magnitude higher 
compared to other body fluids or tissues. The presence of uridine at these high 
concentrations and its correlation with sperm motility suggests a role of uridine in 
spermatogenesis (Pizzorno et al., 2002). 
Uridine can regulate the output of neurites from differentiating neuronal cells and 
intact brain acting through cytidine triphosphate (the final product of the pathway 
uridine→UTP→CTP) as a precursor for phosphatidylcoline biosynthesis and acting 
through UTP as an agonist for P2Y receptors; in fact the stimulation of neurite 
outgrowth depends also on activation of P2Y receptors (Pooler et al., 2005) 
In the clinical setting, uridine is utilized in the treatment of autism with seizures 
and pyrimidine-deficient genetic diseases such as orotic aciduria (Cao et al., 2004). 
Thus, uridine exerts several modulatory and regulatory functions even though no 
clear mechanism has been identified in order to modulate these physiological 
activities (Pizzorno et al., 2002). In fact, specific receptor for uridine are not still 
discovered even if Kimura et al. (2001) postulate the presence of a specific receptor 
for uridine involved in sleep mechanism. On the other hand, extensive evidences 
indicate that there are specific receptors for pyrimidine nucleotides, including UTP, 
UDP and UDP-glucose. 
Pyrimidine nucleotides are important signalling molecules which activate G 
protein-coupled membrane receptors (GPCRs) of the P2Y family. Uracil nucleotide-
sensitive P2Y receptor subtypes may constitute future targets for the treatment of 
certain cancer types, vascular diseases, inflammatory diseases, and 
immunomodulatory intervention. They have also been proposed to play a role in 
neurodegenerative diseases (Brunschweiger et al., 2006). Uracil nucleotides exert 
specific P2 receptor-mediated effects on midbrain-derived human mesencephalic 
neuronal stem/precursor cells and may be used to enhance both proliferation and 
dopaminergic differentiation (Milosevic et al., 2006). In order to induce proliferation 
and dopaminergic differentiation, uracil nucleotides exert their action activating the 
MAPK proteins (Pooler et al., 2005; Milosevic et al., 2006).  
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This effect is abolished by apyrase, an enzyme that degrades nucleotides such as 
UTP and blocked by P2Y receptor antagonists, suggesting that uridine, in addition to 
increasing CTP synthesis, promotes neurite outgrowth by UTP mediated stimulation 
of a P2Y receptor-coupled signalling pathway (Pooler et al., 2005).  
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6. Protective role of purine and pyrimidine compounds exerted 
through a receptor independent mechanism 
 
The brain depends on both glycolysis and mitochondrial oxidative 
phosphorylation for maintenance of ATP levels. The substrate and oxygen 
deprivation associated with hypoxia or ischemia leads to reduced mitochondrial ATP 
synthesis and subsequent decline in cellular energy stores as ATP generation fails to 
meet cellular demands (Jurkowitz et al., 1998). It is presumed that glucose 
deprivation induces depletion of ATP, membrane depolarization, extracellular 
accumulation of excitatory amino acids, excitotoxic calcium overload, loss of 
neuronal homeostasis and degeneration (Ciccarelli et al., 2001). In particular, 
mitochondrial dysfunction and oxidative stress have been implicated in 
neurodegenerative disorders such as Alzheimer’s, amyotrophic lateral sclerosis, 
Huntington’s and Parkinson’s disease (Jurkowitz et al., 1998). Consequently, 
reactions requiring ATP are compromised, including those involved in synthesis of 
macromolecules, ion pumping, and protein phosphorylation (Jurkowitz et al., 1998). 
The loss of homeostasis eventually leads to irreversible cell damage if high-energy 
phosphate reserves are not soon replenished. The level to which ATP falls during 
hypoxia or ischemia has been correlated with the extent of subsequent cellular 
damage and loss of function in both in vitro and in vivo. 
The catabolism of ATP during hypoxia or ischemia results in increases in the 
levels of AMP, IMP, adenosine, and inosine in brain as well as in cultured glia and 
neurons. Adenosine and inosine are released to the extracellular space where 
concentrations may reach high micromolar level (Jurkowitz et al., 1998). Haun et al 
(1996) demonstrate that the combined glucose-oxygen deprivation in rat astrocyte 
cultures, causes an astroglial injury; nevertheless, the somministration of adenosine, 
dramatically reduces cellular injury in the cultures and selective adenosine receptor 
agonists fail to exert a protective effect while adenosine receptor antagonist failed to 
reverse the protective effect of adenosine. Moreover, these authors have revealed that 
inosine is protective at concentrations nearly identical to those of adenosine, whereas 
hypoxanthine and ribose fail to provide protection during the combined glucose-
oxygen deprivation. They also demonstrate that an adenosine deaminase inhibitor, 
reverses the protective effect of adenosine, suggesting that the glioprotective effect 
of adenosine requires degradation of adenosine to inosine. Finally, they demonstrated 
also that dipyridamole, a purine uptake inhibitor, blocked the protective effect of 
both adenosine and inosine, implying an intracellular mechanism (Haun. et al., 
1996). Therefore, adenosine must be metabolized to inosine to exert a protective 
effect without any involvement of adenosine receptor. In fact, adenosine deaminase 
is a cytosolic enzyme, therefore adenosine must enter the cells to be metabolized to 
inosine (Haun et al., 1996). According to these authors, inosine could be 
phosphorolytically cleaved in order to produce the base, hypoxanthine which can be 
converted to inosine 5’-monophosphate, the precursor for adenine nucleotide 
synthesis, in the reaction catalyzed by hypoxanthine-guanine phosphoribosyl-
transferase. However they observe that hypoxanthine has no effect on astroglial 
injury in their model, suggesting preservation of the adenine nucleotide pool is not 
the mechanism by which inosine protects.  
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Therefore, the authors suppose that inosine exerts its protective effect via an 
unknown second intracellular messenger system (Haun et al., 1996). 
Inosine has been previously shown to induce neurons to express a set of growth-
associated proteins and to extend axons in culture and in vivo. In adult rats with 
unilateral cortical infarcts, inosine stimulated neurons on the undamaged side of the 
brain to extend new projections to denervated areas of the midbrain and spinal cord 
(Chen et al., 2002). Other authors have used ROC-1 clonal cell line formed by a 
fusion between rat oligodendroglia and rat C6 astroglial tumor cells and these cells 
are subjected to metabolic stress conditions by glucose deprivation and 
mitochondrial inhibition with the respiratory chain amobarbital. Also these authors 
show that adenosine and inosine are able to protect these cells and for the first time, 
they demonstrate that also guanosine had this protective effect (Jurkowitz et al., 
1998). The effect of adenosine is blocked by coformicin, an inhibitor of adenosine 
deaminase and the protective effect of inosine and guanosine in viability and ATP 
does not occur in the presence of BCX-34, a potent inhibitor of nucleoside 
phosphorylase. Also these authors demonstrate that these compounds have to entry 
the cells where they are metabolized in order to exert the protective effect but they 
suppose that the protective action is not exerted by an intracellular messenger system 
but through the formation of the phosphorylated ribose stemming from the 
phosphorolysis of the nucleoside which is used as an energy source, alternative or 
supplementary to glucose (Fig.7). (Jurkowitz et al.,1998).The pronounced increase 
observed in lactate production in the presence of nucleosides suggests that ribose 
moieties derived from the nucleoside are fueling glycolysis. According to these data, 
they propose the following metabolic pathway: inosine is phosphorolyzed to ribose l-
phosphate and hypoxanthine by purine nucleoside phosphorylase. Three ribose l-
phosphates are isomerized to ribose 5-phosphate, and then converted to two glucose 
6-phosphates and one glyceraldehydes 3-phosphate, via transaldolases and 
transketolases of the pentose phosphate pathway. These phosphorylated 
intermediates enter the glycolytic pathway, yielding a net production of eight 
molecules of ATP per three molecules of ribose 1-phosphate (Jurkowitz et al., 1998). 
Therefore, the phosphorylated ribose stemming from the phosphorolysis of the 
nucleoside can be converted, without energy expense, into energetic intermediates 
and the cells, subjected to metabolic stress conditions, are able to produce ATP and 
preserve their energy charge. 
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Fig.7. Schematic illustration of the uptake and utilization of (deoxy)nucleosides. 
1: adenosine deaminase; 2: purine nucleoside phosphorylase; 3: phosphoribo-
mutase; 4: deoxyRib-5-P aldolase; 5: aldehyde oxidase; 6: acetyl-CoA synthe-
tase; 7: transketolase; 8: transaldolase; 9: PRPP synthetase.  
      (image taken from Giannecchini et al., 2004) 
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Giannecchini et al. (2004) demonstrate that the phosphorylated ribose moiety of 
inosine can be used for energy repletion through anaerobic glycolysis in human 
carcinoma cell line subjected to metabolic stress conditions.  
Shin et al. (2002) demonstrate that not only adenosine and inosine but also 
guanosine is able to protect the death in glucose-deprived immunostimolated 
astrocytes and this protective effect is blocked by the concomitant incubation with 
inhibitors of nucleoside transporter (NBTI and dypiridamole) thus confirming a 
receptor independent mechanism of nucleoside action. 
Excessive generation of H2O2 has been implicated in the pathogenesis of several 
neurodegenerative diseases. In particular, activated astrocytes produce various 
reactive oxygen species (ROS) including H2O2. Excess H2O2 may cause deterioration 
of cellular energy metabolism and cellular redox homeostasis. In cortical neurons, 
H2O2 causes a severe loss of ATP and related adenine nucleotides. Depletion of 
cellular ATP level causes disruption of glutathione (GSH) redox homeostasis, 
because ATP is closely related to the synthesis of the nicotinamide nucleotides 
(NADPH), a critical source of GSH synthesis (Yoo et al., 2005).  
Yoo et al. (2004) demonstrate that adenosine and other purine nucleosides and 
nucleotides including ATP prevent the augmented cell death of astrocytes co-treated 
with H2O2 and glucose deprivation and this protective effect is made via a receptor 
independent mechanism. 
Choi et al. (2006) demonstrate that also uridine is able to restore the intracellular 
ATP levels in the cells subjected to the ischemic conditions and this protective effect 
is attenuated when the cellular uptake of uridine is blocked using an inhibitor of 
nucleoside transporter (NBTI). These authors also demonstrate that the inhibition of 
uridine phosphorylase activity diminishes the uridine-derived preservation of cellular 
ATP levels and cell survival. These data indicate that uridine phosphorylase exists in 
astroglia and has a crucial role in the protective effect of uridine. 
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7. Nucleosides transporters 
 
The intracellular concentration of nucleosides is determined by the enzymes 
involved in their metabolism which are regulated only by the availability of their 
substrates, but of relevant importance is also the efficiency of the nucleoside 
transporters (Giannecchini et al., 2004). Nucleoside transporters are a family of 
proteins with different substrate affinity, tissue distribution, species specificity and 
sensitivity to blockade by pharmacological agents. They are classified as being 
equilibrative (ENT) and concentrative (CNT) nucleoside transporter systems (Fig.8) 
(King et al., 2006).  
 
 
 
Fig.8. Equilibrative (ENT) and concentrative (CNT) nucleoside transporter   
systems 
 
 
 
The ENT family is restricted to eukaryotes, whereas CNT family members are 
also found in eubacteria. Their names reflect the properties of the first members to be 
characterized from mammals: mammalian CNT proteins are cation symporters while 
ENT proteins are facilitated diffusion systems (King et al., 2006). 
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7.1 Equilibrative transporters 
 
The equilibrative transport system mediates nucleoside transport in both 
directions depending on the nucleoside concentration gradient across the plasma 
membrane. The equilibrative transporters are facilitative-diffusion carriers that 
display a broad permeant selectivity, accepting both purine and pyrimidine ribo- and 
deoxyribonucleosides as permeants, whereas the concentrative transporters are 
nucleoside-sodium symporters that are driven by transmembrane sodium gradients 
and exhibit relatively narrow permeant selectivity (King et al., 2006). This class of 
equilibrative transport system is subdivided in two types (es and ei) based on their 
sensitivity to nitrobenzylthioinosine (NBTI). The es transport system is highly 
sensitive to inhibition by NBTI (Ki = 0.1 to 10 nM). In contrast, the ei transport 
system is resistant to NBTI up to 1 µM (Pinto-Duarte et al., 2005). Four transporters 
(ENT1, ENT2, ENT3 and ENT4) belonging to the equilibrative transport system 
have been identified and cloned. ENT1 and ENT3 are susceptible to NBTI, whereas 
this compound does not inhibit ENT2. ENT4 has been identified only recently and its 
transporting characteristics have not been fully determined (Pinto-Duarte et al., 
2005). These four members of the equilibrative transport system are widely 
distributed among various cell types, but the number of molecules of each nucleoside 
transporter depends on the cell and tissue type. All transporters are able to transport 
adenosine, but they have different capacities to transport other nucleosides and 
nucleobases (Pinto-Duarte et al., 2005; Nagasawa et al., 2007). 
Each member of the ENT family consists of 11 hydrophobic transmembrane (TM) 
α-helices arranged in the plasma membrane by such way that the N-terminus is 
cytoplasmic while the C-terminus is located in the extracellular space. These 
transporters are post-trasductionally modified by glycosylation (King et al., 2006). 
The activity of ENTs is controlled by G proteins and protein kinases. Adenosine 
receptors, which are coupled to G proteins and protein kinase-dependent transducing 
systems, appear therefore to be good candidates to modify the levels of their 
endogenous ligand, adenosine (Pinto-Duarte et al., 2005). In particular, A2A 
receptors are coupled to several G proteins and their activation influences at least the 
activities of two types of protein kinases, PKA and PKC.  
The findings that a PKC inhibitor, but not a PKA inhibitor, prevents the 
enhancement of adenosine transport induced by the A2A receptor agonist, and that 
PKC activators per se influence adenosine transport, suggest that A2A receptors 
control ENTs activity in a PKC-dependent manner (Pinto-Duarte et al., 2005). 
It has been also demonstrated that insulin up-regulated the level of ENT2 with no 
involvement of MAP kinases. On the other hand, insulin-induced suppression of 
CNT2 expression was totally blocked by an inhibitor of MEK-1 (PD98059), 
indicating that insulin controls CNT2 level by signalling through the MAPK pathway 
(King et al., 2006). An involvement of growth factors in the regulation of expression 
of nucleoside transporters is demonstrated in murine bone marrow-derived 
macrophages. These cells express both the equilibrative (ENT1, ENT2) and 
concentrative (CNT1, CNT2) nucleoside transporters.  
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Studies performed on human B cell lines have shown that differentiation factors 
such as phorbol esters (PMA) and LPS up-regulate concentrative transport systems, 
but down-regulate the equilibrative transporters in a PKC-dependent manner (King et 
al.,2006). 
 
7.2 Concentrative transporters 
 
The concentrative transport system is Na+-dependent and the movement of the 
nucleoside regardless of its concentration gradient is coupled to that of the sodium 
ion (King et al., 2006). Six functionally different concentrative nucleoside transport 
activities have been described in human cells and they have been named in two 
different ways. The first nomenclature is numerical and follows the order of 
discovery (N1–N6), and the second one is based on the substrate specificity (cit, cif, 
cib, cit-like, cs, csg) (King et al., 2006). The N1-cif activity is purine-selective, the 
N2-cit transport system accepts pyrimidine nucleosides, the N3-cib system transports 
both purine and pyrimidine nucleosides, the N4-cit-like system is selective for 
pyrimidine nucleosides but also accepts adenosine and guanosine, the N5-cs system 
transports adenosine and its analogues, and the N6-csg activity is guanosine-
selective. To date three different proteins responsible for the cit (CNT1), cif (CNT2), 
and cib (CNT3) activities have been identified. Proteins that demonstrate the N4-cit-
like, N5-cs or N6-csg activities have not been identified yet (King et al., 2006). A 
study performed on starved rats has demonstrated that food supply modulates the 
expression level of CNT1 in rat small intestine. It was showed that nucleotide-
deficient diets increased the amount of CNT1 protein in jejunum brush border 
membranes. These findings suggest that the supply of nucleotides modulates CNT1 
expression in a tissue-specific manner (King et al., 2006) Hormonal regulation of 
nucleoside transport activity has been reported in several tissues and cell types. 
Exposition of cultured chromaffin cells to lymphocyte T3 cells, results in an increase 
in the number of nucleoside transporters and stimulation of adenosine transport. 
Moreover, a study on rat liver documents up-regulation of nucleoside transport by 
glucagon through a mechanism involving membrane hyperpolarization (King et al., 
2006).  
A study performed on rats, shows that the mRNA levels of rENT1, rENT2, 
rCNT1, and CNT2 are significantly altered in diabetic heart, liver, and kidney. 
Experiments performed on cultured rat T and B lymphocytes demonstrate that 
nucleoside transporters expression levels are independently and differentially 
regulated by glucose and insulin. 
It appears that in rat lymphocytes the expression level of rENT2 and rCNT2 
highly depends on insulin but is not affected by changes in extracellular glucose 
level, whereas the expression level of rENT1 is sensitive to extracellular glucose 
level but not to insulin (King et al., 2006). Insulin is also able to stimulate Na+-
dependent uridine uptake by a process consistent with de novo synthesis of the 
carrier protein (King et al., 2006). 
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MATERIALS 
 
 
RPMI medium 1640, L-glutamine, antibiotics, trypsin (2.5%) and trypan blue stain 
(0.4 %) were from Cambrex Bio Science (Walkersville, MD, USA). Dulbecco’s 
modified Eagle medium without glucose (DMEM) and foetal bovine serum (FBS) 
were from Gibco (Berlin, Germany). Dulbecco’s phosphate buffered saline (PBS), 
oligomycin, nitrobenzylthioinosine (NBTI), 8-cyclopentenyl-1,3-dipropylxanthine 
(DPCPX), xanthine oxidase (EC 1.1.3.22), alcohol dehydrogenase (EC1.1.1.1) and 
lactic dehydrogenase (EC 1.1.1.27) were purchased from Sigma (St Louis, MO, 
USA). Mycoplasma removal agent was from ICN Biomedicals (Costa Mesa, CA, 
USA). Glutamate–pyruvate transaminase (EC 2.6.1.2) was from ICN Biomedicals 
(Irvine, CA, USA). [2-14C]Uridine (53mCi/mmol) was from Moravek Biochemicals 
(Brea, CA, USA). [2-14C]Uracil (54 mCi/mmol), [2-14C] cytidine (53.8 mCi/mmol), 
[8-14C] adenine (55 mCi/mmol), [8-14C] hypoxanthine (49,5 mCi/mmol), [2-14C]5-
fluorouracil (5-FU) (53 mCi/mmol), bases, nucleosides, and nucleotides were 
purchased from Sigma (St. Louis, MO, USA). HiSafe II scintillation liquid was 
purchased from LKB Pharmacia (Uppsala, Sweden). Polyethyleneimmine (PEI)-
cellulose precoated thin-layer plastic sheets (0.1 mm thick) were purchased from 
Merck (Darmstadt, Germany) and prewashed once with 10% NaCl and three times 
with deionized water before use. DE81 filter papers were from Whatman (Kent, UK). 
Human astrocytoma cells (ADF) were a kind gift of Dr. W. Malorni, Istituto 
Superiore di Sanita` (Roma, Italy). Deoxycoformycin (dCF) was provided by Dr. O. 
Sanfilippo (Milan, Italy). 5-(phenylthio) acyclouridine (PTAU) was kindly provided 
by Dr. Mahmoud H. el Kouni, University of Atlanta, USA. C18 ultrasphere ODS 
HPLC column was from Beckman Instruments (Fullerton, CA, USA). All other 
chemicals were of reagent grade. 
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METODS 
.1.Treatment of cells 
 
Human astrocytoma cells (ADF) were routinely grown in RPMI medium with 
10% FBS and 2% antibiotics at 37°C in a humidified 5% CO2/95% air atmosphere. 
The contamination of ADF cells by Mycoplasma, which is known to possess 
adenosine-phosphorylase activity (Hatanaka et al., 1975), was tested through the 
assay of adenosine-phosphorylase (EC 2.4.2.1). Tests for Mycoplasma contamination 
were made in routinely cultured cells and in cells exposed for 3 passages to 
Mycoplasma removal agent (0.5 mg/ml). Overall, the results excluded any 
contamination by Mycoplasma. 
The experiments were performed with cells (approximately 1,500,000) kept in 35-
mm plates for 10 min in 0.5 mL of serum-free DMEM medium without glucose in 
the absence or presence of 0.1 µM oligomycin. Cells were washed twice with 2 mL 
cold physiological solution. Some plates were treated as described in section 9.2.2 
for the extraction of nucleotides whereas 0.5 mL of DMEM medium either alone or 
containing the following metabolites were added to other plates: glucose (from 0.5 to 
10 mM), inosine (from 0.25 to 10 mM), adenosine (from 0.25 to 10 mM), uridine 
(from 1 to 10 mM), guanosine, cytidine, hypoxantine, ribose, and deoxyinosine at a 
final concentration of 10 mM. When nitrobenzylthioinosine (NBTI) or 8-
cyclopentenyl-1, 3-dipropylxanthine (DPCPX) were present, their final 
concentrations were 10 and 100 mM, respectively. When deoxycoformycin (dCF) 
and 5-(phenylthio) acyclouridine (PTAU) were present in the incubation mixture, 
their final concentrations were 1 and 50 µM, respectively. After 30 min incubation, 
medium was collected and kept at -20 °C for the determination of lactate; cells were 
then treated as described below for the extraction of nucleotides. 
 
2. Extraction and measurement of intracellular adenine nucleotides 
 
Cells were subjected to the treatment described in the previous section. After 
treatment, the incubation medium was removed, and cells were washed twice with 2 
mL of cold physiological solution. For the extraction of nucleotides, 0.1 mL of ice-
cold 0.6 M perchloric acid was added to each plate and kept for 15 min; cells were 
harvested with a cell scraper, and the suspension was centrifuged in an Eppendorf 
Microfuge. The supernatant is neutralized with 15 µL of 3.5 M K2CO3. After 
centrifugation in a Microfuge, the supernatant was analyzed by HPLC: the analysis 
was performed with a Beckman System Gold apparatus, consisting of 2 HPLC 
pumps, a mixing chamber, an injector valve, and a diode-array detector. An 
Ultrasphere C-18 (Beckman) column (4.6 mm × 25 cm, 5-µm particle size) was used 
as described in Micheli et al. (1999).  
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3. Determination of lactate 
 
The culture medium, collected as described in section 8.2.1, was subjected to the 
spectrophotometric assay for the determination of lactate (Martı et al., 1997). The 
reaction mixture contained in a final volume of 0.5 mL, 200 mM glycylglycine–40 
mM glutamate (pH 10), 4 mM NAD+, 27 U of lactic dehydrogenase (5248 U/mL), 7 
U of glutamate–pyruvate transaminase (1773 U/ mL), 90 µL of culture medium, and 
20 mM Tris–HCl pH 7.4. 
 
4. Preparation of cell extracts and enzyme assays 
 
In order to obtain the extracts for the determination of enzyme activities, the cells 
were treated with trypsin (0.25%) and incubated for 5’ at 37°, after the incubation 4 
ml of RPMI 1640 medium was added. The suspension was centrifuged for 5’ at 900g 
and then the supernatant was removed while the pellet was washed with PBS and the 
cell suspension was centrifuged for 5’ at 900g, washed with 100 mM Tris-HCl pH 
7.4 and then subjected to ultrasonic treatment and centrifuged for 30 min at 4°C at 
39,000g (Giorgelli et al., 2000). All enzyme assays were performed at 37°C. For 
each sample, at least 2 determinations with different amounts of cell extract were 
carried out. Linearity with time and protein concentration was observed for all 
enzyme assays. A spectrophotometric method was applied for the assay of purine 
nucleoside phosphorylase (EC 2.4.2.1), adenosine deaminase (EC 3.5.4.4) and 
deoxyriboaldolase (EC 4.1.2.4). A radioenzymatic assay was applied to measure the 
activity of uridine phosphorylase (EC 2.4.2.3), cytidine deaminase (EC 3.5.4.5), 
adenosine-phosphorylase (EC 2.4.2.1), adenosine kinase (EC 2.7.1.20), cytosolic 
IMP/GMP-specific- 5’-nucleotidase (cN II) (EC 3.1.3.5), adenine phosphoribosyl 
transferase (EC 2.4.2.7), hypoxanthine phosphoribosyl transferase (EC 2.4.2.8), 
uridine-cytidine kinase (EC 2.7.1.48). 
 
I. Purine nucleoside phosphorylase (PNP) 
The reaction mixture (0.5 mL) contained 100 mM phosphate buffer, pH 7.4, 0.3 
mM inosine, 0.02 U of xanthine oxidase (1.8 U/mL), and 30–70 µg of cell extract. 
The change in optical density at 293 nm was followed against a reference cuvette 
in which inosine was substituted by water.  
 
II. Adenosine deaminase (ADA)  
The reaction mixture (0.5 mL) contained 100 mM Tris–HCl, pH 7.4, 0.08 mM 
adenosine, and 30–70 µg of cell extract. The change in optical density at 265 nm 
was followed against a cuvette in which adenosine was substituted by water.  
 
III. Deoxyriboaldolase  
The reaction mixture (0.5 mL) contained 70 mM Tris–HCl, pH 7.4, 1.5 mM 
dithiothreitol, 0.22 mM NADH, 11 U of alcohol dehydrogenase (1098 U/mL), 2 
mM deoxyRib-5-P, and from 0.3 to 0.6 µg of cell extract. The assay was performed 
spectrophotometrically, by monitoring the change in optical density at 340 nm, 
against a reference cuvette in which deoxyRib-5-P was substituted by water.  
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IV. Uridine phosphorylase (UPase) 
The reaction mixture (50 µL) contained 5 mM phosphate buffer, pH 7.4, 1 mM [2-
14C] uridine (3720 DPM/nmol), from 75 to 150 µg of cell extract, and 30 mM Tris–
HCl, pH 7.4. At 0, 10, 20, and 30 min incubation, 10 µL aliquots were withdrawn 
and spotted on a PEI-cellulose plate which was developed overnight with n-
propanol/TCA(100% saturation)/NH3/H2O (75/0.7/5/20, v/v). The spots 
corresponding to uracil (for uridine phosphorylase) and uridine (for cytidine 
deaminase) were cut and the radioactivity counted, after addition of 8 mL of liquid 
scintillation counter. 
 
V.   Cytidine deaminase 
The reaction mixture (50 µL) contained 60 mM Tris–HCl, pH 7.4, 3 mM 
dithiothreitol, 0.25 mM [2-14C] cytidine (6072 DPM/nmol), 5 mM ZnSO4, and 
from 10 to 20 µg of cell extract. The aliquots were treated as described for the 
UPase assay. 
 
VI. Adenosine phosphorylase  
The reaction mixture (50 µL) contained 0.5 mM [8-14C] adenine (15,000 
dpm/nmol), deoxyribose-1-phosphate 0.5 mM, dCF 6 µM and from 10 to 20 µg of 
cell extract. At 0, 10, 20, and 30 min incubation, 10 µL aliquots were withdrawn 
and spotted on a PEI-cellulose plate which was developed for three hours in 0.1M 
(NH4)2SO4.  
 
VII. Adenosine kinase (AK).  
The reaction mixture (50 µL) contained 54µM [8-14C] adenosine (10,000 
dpm/nmol), 1 µM dCF, 1 mM ATP, 1.5 mM MgCl2 and from 10 to 20 µg of 
protein. At 0, 10, 20, and 30 min incubation, 10 µL aliquots were withdrawn and 
spotted on a DE 81 filter paper which was washed 15 min in 1 M ammonium 
formate and 10 min in 2 changes of water. The disks were dried and counted for 
radioactivity. 
 
VIII. Nucleoside phosphotransferase activity of cytosolic 5’-nucleotidase   
The reaction mixture (50 µL) contained 1 mM [8-14C] inosine (4,300 dpm/nmol), 2 
mM IMP, 4 mM dithiothreitol (DTT), 5 mM ATP, 20 mM MgCl2 and 15 to 30 ug 
of protein. The aliquots were treated as described for the AK assay. 
 
IX. Hypoxanthine phosphoribosyl transferase (HPRT)  
The reaction mixture (50 µL) contained 1 mM [8-14C] hypoxanthine (9100 
dpm/nmol), 2.6 mM 5-phospho-D-ribosyl-1-pyrophosphate, 2 mM MgCl2, 2mM 
DTT, 50 mM Tris-HCl pH 7.4 and from 15 to 30 µg of protein. The aliquots were 
treated as described for the AK assay. 
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X. Adenine phosphoribosyl transferase (APRT). 
The reaction mixture (50 µL) contained 0.25 mM [8-14C] adenine (15,000 
dpm/nmol), 2.5 mM PRPP, 10 mM MgCl2, 5 mM DTT, 50 mM Tris-HCl pH 7.4 
and from 20 to 40 µg of protein. The aliquots were treated as described for the AK 
assay. 
 
XI.   Uridine kinase (UK). 
   The reaction mixture (50 µL) contained 1 mM [2-14C] uridine (3720 DPM/nmol), 
10mM MgCl2, 5mM ATP, 50 mM Tris-HCl pH 7.4 and from 30 to 40 µg of 
protein. The aliquots were treated as described for the AK assay. 
 
XII. Cytidine kinase (CK). 
The reaction mixture (50 µL) contained, 0.25 mM [2-14C] cytidine (6072 
DPM/nmol), 10 mM MgCl2, 5 mM ATP, 50 mM Tris-HCl pH 7.4 and from 10 to 
20 µg of protein. The aliquots were treated as described for the AK assay.  
 
One unit of enzyme activity was the amount of enzyme which catalyzes the 
formation of 1 µmol of product/min under the adopted assay conditions 
 
5.Incubation of human astrocytoma cells with purine and pyrimidine 
compounds 
 
The experiments were performed with cells (approximately 1,500,000) kept in 35-
mm plates for different times in 0.5 ml of serum-free DMEM medium. In order to 
test the adenine salvage synthesis, cells were incubated for different times with 50 
µM [8-14C] adenine (15,000 dpm/nmol) alone or in the presence of either 100 µM 
inosine, cytidine or deoxyinosine, or uridine (from 50 to 200 µM); when 5-
(phenylthio)acyclouridine (PTAU) was present in the incubation mixture, its final 
concentrations was 50 µM. To test hypoxanthine salvage synthesis, cells were 
incubated with 50 µM [8-14C] hypoxanthine alone or in the presence of 100 µM 
uridine. For pyrimidine salvage, cells were incubated with 50 µM [2-14C] uracil 
(35,000 dpm/nmol) alone or in the presence of 100 µM inosine, or with 100 µM [2-
14C] uridine (5600 dpm/nmol) alone or in the presence of 50 µM adenine. The 
formation of 5-FU nucleotides was followed by incubating 50 µM [2-14C] 5-
flurouracil (5FU) (10,500 dpm/nmol) either alone or in the presence of 100 µM 
inosine. In order to test the cytidine effect on the purine salvage synthesis, cells were 
incubated for 30’ in the presence or in the absence of 0.25, 0.5 1mM cytidine; at the 
end of incubation the serum-free DMEM medium was removed and cells were 
incubated for the indicated times with 50 µM [8-14C] adenine (15,000 dpm/nmol) 
alone or in the presence of uridine.  
To test the cytidine effect on pyrimidine salvage, cells were incubated for 30’ in 
the presence or in the absence of 1 mM cytidine; at the end of incubation the serum-
free DMEM medium was removed and cells were incubated for the indicated times 
with 50 µM [2-14C]uridine (5600 dpm/nmol) alone. At the different times of 
incubation, the medium was removed, and cells were washed twice with 2 ml of cold 
physiological solution. For the extraction of purine and pyrimidine compounds, cells 
were treated as already described in section 9.2.2.  
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After centrifugation in a Microfuge, 50 µl of the supernatant was applied to a PEI-
cellulose plate which was developed overnight with n-propanol/TCA (100% 
saturation)/NH3/H2O (75/0.7/5/20, v/v). The zones corresponding to radioactive 
AMP + ADP + ATP (TAN) (adenine salvage) or IMP (hypoxanthine salvage) and 
radioactive UMP + UDP + UTP (TUN) (uracil and uridine salvage) or FUMP+ F-
UDP + F-UTP (5-FU activation) were cut and the radioactivity counted, after 
addition of 8 ml of liquid scintillation counter. In order to test the CTP formation in 
cells incubated for 30’ with cytidine, the cells were incubated for 30’ with 500 µL of 
serum-free DMEM medium in the presence or absence of cytidine.  
After the incubation cells were treated for the extraction of purine and pyrimidine 
compounds and the CTP intracellular level was determined by HPLC technique as 
described in section 9.2.2. 
 
6. Other methods 
 
For the counting of cells adhering to the plate and for the trypan blue staining of 
cells subjected to different treatments, the medium was withdrawn, in order to 
remove detached cells, and cells remaining adherent to the plate were washed with 
cold physiological solution. A 0.5-mL portion of 0.025% trypsin is then added and 
kept for few minutes at 37 °C. To measure the number of adhering cells, the cell 
suspension is collected, diluted in an appropriate volume of RPMI medium, and cells 
counted under a microscope in a Bürker chamber. To measure the percentage of dead 
cells among those adhering to the plates, the cell suspension is centrifuged and then 
re-suspended in 2.5 mL of PBS. Cell suspensions (0.5 mL) are mixed with 0.5 mL of 
0.4% trypan blue solution, and after 5 min, the stained non-viable cells are counted 
under a microscope in a Bürker chamber. 
Proteins were determined according to Bradford (1976), using bovine serum 
albumin as standard. The statistical analyses are performed by using the unpaired t-
test. 
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RESULTS 
 
 
1. Cell energy charge without and with treatment with oligomycin 
 
To shed light on the protective role of purine nucleosides during ischemia or brain 
insults, we have used a human astrocytoma cell line (ADF) which has been subjected 
to metabolic stress conditions by exclusion of glucose and pre-incubation for 10 min 
with oligomycin (an inhibitor of oxidative phosphorylation). The determination of 
the intracellular adenylate pool indicates that treatment for 10 min with 0.1 µM 
oligomycin in a culture medium devoid of glucose brings about a decrease in the 
ADF cell energy charge ([ATP] + (1/2)[ADP]/[ATP] +[ADP] + [AMP]) from 0.89 ± 
0.04 (n = 10) to 0.73 ± 0.09 ( p < 0.0001, n = 22). After removal of the culture 
medium, a further incubation for 30 min with a medium devoid of glucose in the 
absence of oligomycin results in a further decrease in the cell energy charge up to 
0.44 ± 0.15 (p < 0.0001, n = 22), thus indicating that, in these conditions, cells are 
not able to use the nutrients present in the medium (mainly aminoacids) as energy 
source, and suggesting that the inhibition exerted by oligomycin is not overcome by 
the removal of the inhibitor.  
 
2. Effect of glucose and nucleosides on energy repletion after treatment 
with oligomycin 
 
The adenylate pool was measured in cells previously subjected to a 10 min 
treatment with oligomycin and then suspended for 30 min in a medium containing 
different metabolites. Results indicate that glucose is able to counteract the fall in the 
ATP content which is observed when the culture medium was devoid of substrates 
metabolizable through fermentation (Fig. 9A). Concomitantly, a marked decrease in 
AMP levels is observed, thus resulting in a restoration of the cell adenylate charge to 
values similar to those found for untreated cells. The assay of lactate in the 
incubation medium indicates that the ATP pool is restored through anaerobic 
glycolysis (Fig. 9B). The addition of inosine in the incubation medium (in a range of 
concentrations from 10 to 0.25 mM) exerts a protective action comparable to that 
observed with glucose (Fig. 10A). Indeed, an enhancement of ATP content and a 
decrease in AMP levels are observed. While guanosine, being a carrier of the sugar 
moiety is able to exert a protective action, hypoxanthine and ribose are not. Also 
deoxyinosine has no effect on the preservation of the ATP pool. Again, anaerobic 
glycolysis appears to be the metabolic pathway through which cells are able to 
restore the ATP level (Fig. 10B). Also adenosine restores the ATP pool through 
anaerobic glycolysis, independently of the presence of DPCPX, which is an 
antagonist of adenosine A1, A2A, A2B, and, in the micromolar range, A3 receptors 
(Klotz, 2000) (Fig.11). Besides purine, also pyrimidine nucleosides, such as uridine, 
and to a lesser extent cytidine, when added to the incubation medium exert a 
protective action (Fig. 12A), which is related to their capability to restore the ATP 
pool through anaerobic glycolysis, as evidenced by the formation of lactate (Fig. 
12B).  
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To address the question about the presence of a receptor-independent mechanism 
of nucleoside action, cells were treated with oligomycin both in the presence or 
absence of an inhibitor of nucleoside transporter (NBTI). The presence of 10 µM 
NBTI in the culture medium does not exert any significant effect on control cells and 
does not affect the protective action of glucose, but counteract significantly the 
efficacy of inosine and uridine (Fig.13). The number of cells adhering to the plates 
after 10 min treatment with oligomycin is not significantly different as compared to 
control untreated cells. A further incubation for 30 min in the absence of effectors 
brings about a significant decrease of the adhering cell number. The presence of 
glucose, inosine, and uridine exert a rescue effect, the number of adhering cells being 
comparable to that of untreated cells (Fig. 14A). Although not statistically significant 
(unless when inosine is present), in the incubation performed in the absence of 
effectors, also the percentage of dead cells appears to be consistently greater than in 
the presence of glucose, inosine and uridine (Fig. 14B)  
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Fig.9. Effect of glucose on the adenylate energy charge and lactate production in 
astrocytoma cells subjected to ischemic conditions. Cells were previously treated for 
10 min in DMEM medium with 0.1 µM oligomycin, then medium was removed, the 
cells were washed and DMEM medium was added (for 30 min) either with no 
addition or with the indicated amount of glucose. (Panel A) Histograms indicate the 
amount of AMP (black bar), ADP (grey bar) and ATP (dashed bar). The numbers 
indicate the adenylate energy charge (±S.D.). (Panel B) Histograms indicate the 
amount of lactate formed in the DMEM medium alone or supplemented with 
glucose. Number of experiments (n): n = 22 (0); n = 10 (0.5 mM); n = 6 (1 mM); n = 
4 (2.5 mM); n = 4 (5 mM); n = 20 (10 mM). Statistical significance of cell adenylate 
energy charge and lactate content vs. cells with no addition: ***p < 0.0001; **p < 
0.001;*p < 0.05. 
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Fig.10. Effect of inosine, guanosine, deoxyinosine, ribose and hypoxanthine on the 
adenylate energy charge and lactate production in astrocytoma cells subjected to 
ischemic conditions. Cells were previously treated for 10 min in DMEM medium 
with 0.1 µM oligomycin, then medium was removed, the cells were washed and 
DMEM medium was added (for 30 min) either with no addition or with the indicated 
amount of inosine (Ino), guanosine (Guo), deoxyinosine (dIno), hypoxanthine (Hyp) 
and ribose (Rib). (Panel A) Histograms indicate the amount of AMP (black bar), 
ADP (grey bar) and ATP (dashed bar). The numbers indicate the adenylate energy 
charge (± SD). (Panel B) Histograms indicate the amount of lactate formed in the 
DMEM medium alone or supplemented with the indicated compound. Number of 
experiments (n): n = 22 (0); n = 12 (0.25 mM Ino); n = 11 (0.5 mM Ino); n = 6 (1 
mM Ino); n = 4 (5 mM Ino); n = 14 (10 mM Ino); n = 6 (Guo); n = 6 (dIno); n = 4 
(Hyp); n = 4 (Rib). Statistical significance of cell adenylate energy charge and lactate 
content vs. cells with no addition: ***p < 0.0001; **p < 0.001;*p < 0.05. 
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Fig.11. Effect of adenosine on adenylate energy charge and lactate production in 
astrocytoma cells subjected to ischemic conditions. Cells were previously treated for 10 min 
in DMEM medium with 0.1 µM oligomycin, then medium was removed, the cells were 
washed and DMEM medium was added (for 30 min) either alone or with 0.25, 0.5, 1 and 10 
mM adenosine (Ado). Parallel incubations were also performed in which 100 µM DPCPX 
was added to the culture medium. (Panel A) Histograms indicate the amount of AMP (black 
bar), ADP (grey bar) and ATP (dashed bar). The numbers indicate the adenylate energy 
charge (± S.D.). (Panel B) Histograms indicate the amount of lactate formed in the DMEM 
medium alone or supplemented with adenosine. Number of experiments (n): n = 22 (without 
Ado); n = 6 (with Ado and/or DPCPX). Statistical significance of cell adenylate energy 
charge and lactate content vs. cells with no addition: ***p < 0.0001; **p < 0.001; *p < 0.05; 
ns = no significant difference was found in samples with and without DPCPX. 
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Fig.12. Effect of pyrimidine nucleosides on the adenylate energy charge and lactate 
production in astrocytoma cells subjected to ischemic conditions. Cells were 
previously treated for 10 min in DMEM medium with 0.1 mM oligomycin, then 
medium was removed, the cells were washed and DMEM medium was added (for 30 
min) either with no addition or with the indicated amount of uridine (Urd) or cytidine 
(Cyt). (Panel A) Histograms indicate the amount of AMP (black bar), ADP (grey 
bar) and ATP (dashed bar). The numbers indicate the adenylate energy charge 
(±S.D.). (Panel B) Histograms indicate the amount of lactate formed in the DMEM 
medium alone or supplemented with the indicated compound. Number of 
experiments (n): n = 22 (0); n = 6 (1 mM Urd); n = 5 (5 mM Urd); n = 12 (10 mM 
Urd); n = 15 (Cyt). Statistical significance of cell adenylate energy charge and lactate 
content vs. cells with no addition: ***p < 0.0001; *p < 0.05. 
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Fig.13. Adenosine, inosine and uridine must enter astrocytoma cells in order to 
preserve ATP pool. Cells were previously treated for 10 min in DMEM medium with 
0.1 µM oligomycin, then medium was removed, the cells were washed and DMEM 
medium was added (for 30 min) either alone or with the indicated amount of 
adenosine, inosine and uridine. Parallel incubations were also performed in which 10 
µM NBTI was added to the culture medium. (Panel A) Histograms indicate the 
amount of AMP (black bar), ADP (grey bar) and ATP (dashed bar). The numbers 
indicate the adenylate energy charge (±S.D.). (Panel B) Histograms indicate the 
amount of lactate formed in the DMEM medium alone or supplemented with the 
indicated compound. Number of experiments (n): n = 22 (0); n = 6 (Gluc); n = 6 
(Ino); n = 6 (1 mM Urd); n = 9 (Gluc+ NBTI; Ino+ NBTI); n = 9 (Urd+ NBTI). 
Statistical significance of cell adenylate energy charge and lactate content in samples 
with and without NBTI: **p < 0.001; *p < 0.05. ns = not significant. 
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Fig.14. The presence of inosine and uridine improves viability of astrocytoma cells 
undergoing ischemic conditions. Cells were previously treated for 10 min in DMEM 
medium with (treated) or without (untreated) 0.1 µM oligomycin, then medium was 
removed, the cells were washed and DMEM medium was added (for 30 min) either 
alone or with glucose, inosine and uridine. The number of cells still adhering to the 
plates was counted (Panel A). The percentage of dead cells, evaluated by the trypan 
blue staining technique, is also reported (Panel B). For each bar n = 4. Statistical 
significance vs. cells treated with oligomycin with no addition: **p < 0.001; *p < 
0.05. 
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3. Activity of enzymes involved in the catabolism of nucleosides 
 
The activity of enzymes involved in the catabolism of nucleosides was measured 
(Table 1).  
 
 
Table 1 
Enzyme Specific activity (U/mg) 
Purine nucleoside phosphorylase (PNP) 21.1 × 10-3 
Adenosine deaminase (ADA) 7.1 ×10-3 
Deoxyriboaldolase 1.1×10-3 
Uridine phosphorylase (UPase) 4.3×10-3 
Cytidine deaminase 0.32×10-3 
 
 
The results indicate that deoxyinosine, inosine and guanosine can be 
phosphorolytically cleaved by purine nucleoside phosphorylase. Also uridine may be 
subjected to a phosphorolytic cleavage by the action of uridine phosphorylase. 
Although in a low amount, also cytidine deaminase and deoxyriboaldolase are 
present in ADF cells. The presence of adenosine deaminase indicates that adenosine 
may be deaminated to inosine.  
To address the question about the intracellular destiny of the nucleoside 
compounds, cells were treated with oligomycin in the presence of a dCF and PTAU 
which are potent inhibitors of adenosine deaminase and uridine phosphorylase, 
respectively. The presence of 1 µM dCF and 50 µM PTAU, significantly affects the 
efficacy of adenosine and uridine, respectively (Fig.15). 
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Fig.15. The presence of dCF and PTAU counteracts significantly the efficacy of 
adenosine and uridine, respectively. Cells were previously treated for 10 min in 
DMEM medium with 0.1 µM oligomycin, then medium was removed, the cells were 
washed and DMEM medium was added (for 30 min) either alone or with the 
indicated amount of adenosine and uridine. Parallel incubations were also performed 
in which 1 µM dCF and 50 µM PTAU were added to the culture medium. (Panel A) 
Histograms indicate the amount of AMP (black bar), ADP (grey bar) and ATP 
(dashed bar). The numbers indicate the adenylate energy charge (±S.D.). (Panel B) 
Histograms indicate the amount of lactate formed in the DMEM medium alone or 
supplemented with the indicated compounds. Number of experiments (n): n = 22 (0); 
n = 6 (Ado); n = 6 (Ado+ dCF); n = 6 (Urd); n = 6 (Urd+ PTAU). Statistical 
significance of cell adenylate energy charge and lactate content in samples with and 
without dCF (plus Ado) or PTAU (plus Urd): *p < 0.05. 
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4. Determination of purine and pyrimidine salvage in ADF cells. 
 
To test the adenine salvage pathway, ADF cells were incubated at different times 
with radioactive adenine alone or in the presence of either inosine (100 µM), dIno 
(100 µM), or uridine (from 50 to 200 µM) (Fig.16). The time course of nucleotide 
formation was followed. Exogenous uridine and, to a lesser extent inosine, activate 
the salvage of exogenous adenine in ADF cells. The activation exerted by uridine is 
concentration-dependent. dIno is not able to activate the salvage of exogenous 
adenine. ADF were also incubated at different times with radioactive adenine in the 
presence of cytidine or with uridine in the presence of the inhibitor of uridine 
phosphorylase, PTAU. Cytidine has only a moderate effect on adenine salvage and 
the presence of PTAU significantly affects the activation of adenine salvage exerted 
by uridine (Fig.17) 
To test hypoxanthine salvage synthesis, cells were incubated with radioactive 
hypoxanthine alone or in the presence of uridine (Fig.18); exogenous uridine 
activates the salvage of exogenous hypoxanthine in ADF cells. 
To test the pyrimidine salvage pathway, ADF cells were incubated at different 
times with radioactive uracil and fluorouracil alone or in the presence of inosine or 
deoxyinosine, or with radioactive uridine alone or in the presence of adenine. 
Exogenous inosine favours 5-FU (antitumoral agent) activation and uracil salvage, 
while dIno not activate the salvage of exogenous uracil (Fig.19). Finally, fig.20 
shows that the transformation of exogenous uridine into endogenous uracil 
nucleotides in ADF cells is consistently lowered by exogenously added adenine. 
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Fig.16. Time course of total adenine nucleotide (TAN) formation from adenine in 
cultured human astrocytoma cells. ADF cells were incubated with 50 µM [8-14C] 
adenine (15,000 dpm/nmol) in the absence (○) and in the presence of 100 µM inosine 
(●), or 100 µM uridine (■), or 100 µM deoxyinosine (▲). The inset shows the rate of 
TAN formation from adenine at the indicated concentrations of uridine. Number of 
experiments (n): n = 22 (control); n = 6 (Urd); n=6 (Ino); n=3 (dIno). 
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Fig.17. Time course of total adenine nucleotide (TAN) formation from adenine in 
cultured human astrocytoma cells. ADF cells were incubated with 50 µM [8-14C] 
adenine (15,000 dpm/nmol) in the absence (o) and in the presence of either 100 µM 
cytidine (▲) or 100 µM uridine alone (■) and in the presence of 50 µM PTAU (□). 
Number of experiments (n): n= 3 (control); n = 6 (Urd); n = 3 (Urd+PTAU); n= 3 
(Cyt). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 72 
 
 
Fig.18. Time course of total adenine nucleotide (TAN) formation and IMP formation 
from hypoxanthine in cultured human astrocytoma cells. ADF cells are incubated 
with 50 µM [8-14C] hypoxanthine (15,000 dpm/nmol) in the absence (open symbols) 
and in the presence (closed symbols) of 100 µM uridine. IMP (▲,∆); 
AMP+ADP+ATP (○, ●). Number of experiments (n): n = 3 (Hyp); n = 3 (Hyp+Urd). 
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Fig.19. Time course of total uracil nucleotide (TUN) formation from uracil and of 5-
FU nucleotide formation from 5-FU in cultured human astrocytoma cells. ADF cells 
were incubated with 50 µM [2-14C] uracil (35,000 dpm/nmol) (○, ●, ■) or with 50 
µM [2-14C] 5-FU (10,500 dpm/nmol) (∆, ▲) in the absence (○,∆) and in the presence 
of 100 µM inosine (●, ▲) or 100 µM deoxyinosine (■). Number of experiments (n): 
n = 3 (Ura); n = 3 (5FU); n=3 (Ura+Ino); n=3 (5FU+Ino); n=3 (Ura+dIno). 
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Fig.20. Time course of total uracil nucleotide (TUN) formation from uridine in 
cultured human astrocytoma cells. ADF cells are incubated with 100 µM [8-14C] 
uridine (5,600 dpm/nmol) in the absence (o) and in the presence of 50 µM adenine 
(●). Number of experiments (n): n = 3 (Urd); n = 3 (Urd+Ade). Statistical 
significance vs cells not incubated with adenine: *p < 0.05. 
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5. Activity of enzymes involved in the purine and pyrimidine salvage. 
 
The activity of enzymes involved in the purine and pyrimidine salvage was 
measured (Table 2).  
 
Table 2 
Enzyme Specific activity U/mg 
Uridine kinase (UK) 13.38 × 10-3 
Cytidine kinase (CK) 5.25× 10-3 
Hypoxanthine phosphoribosyltransferase 
(HPRT) 
5.35× 10-3 
Adenine  phosphoribosyltransferase 
(APRT) 
9.39× 10-3 
 
The results indicate that uridine and cytidine can be phosphorylated by their 
respective kinases in order to produce UMP and CMP. Adenine and hypoxanthine 
could be converted into IMP and AMP by their respective 
phosphorybosiltransferases.   
 
6. Effect of CTP on the purine and pyrimidine salvage synthesis 
 
In order to enrich the cells with CTP and to test the effect of the pyrimidine 
nucleotide on the purine salvage synthesis, cells were incubated for 30 min in the 
presence of cytidine at different concentrations; at the end of incubation the medium 
was removed and cells were incubated for the indicated times with radioactive 
adenine alone or in the presence of uridine. The pre-incubation with cytidine leads to 
an activation of the adenine salvage pathway in a concentration dependent manner, 
only in the presence of uridine as ribose phosphate donor (Fig.21). The intracellular 
concentration of CTP formed in cells incubated for 30 min with cytidine, was 
evaluated by HPLC analysis and a direct correlation between the extracellular 
cytidine added in the medium and the intracellular CTP formation was observed 
(Table 3). 
To test the CTP effect on pyrimidine salvage, cells were incubated for 30 min in 
the presence of 1 mM cytidine; at the end of incubation the medium was removed 
and cells were incubated for the indicated times with radioactive uridine. The pre-
incubation with cytidine leads to a strong inhibition of the uridine salvage pathway 
(Fig.22). 
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Fig.21. Time course of total adenine nucleotide (TAN) formation from adenine in 
cultured human astrocytoma cells pre-incubated with cytidine at different 
concentrations. ADF cells were pre-incubated for 30 min in the presence or absence 
of cytidine 1 (●, ♦), 0.5 (▲) and 0.25 mM (■) and incubated at different times with 
50 µM [8-14C] adenine (15,000 dpm/nmol) in the absence (open symbols) and 
presence of 100 µM cold uridine (closed symbols). Number of experiments (n): n = 3 
(control); n = 3 (cyt 0.25 mM); n=3 (cyt 0.5 mM); n=6 (cyt 1 mM). Statistical 
significance vs cells not enriched with CTP: *p < 0.05. 
 
 
 
 
Table 3. Correlation between the extracellular cytidine added in the medium and the 
intracellular CTP formation 
 
Table 3 
Extracellular cytidine (mM) Intracellular CTP (nmol/106 cells) 
0,25 0,35 
0,5 0,68 
1 0,81 
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Fig.22. Time course of total uracil nucleotide formation from uridine in cultured 
human astrocytoma cells pre-incubated in the presence of cytidine 1 mM. ADF cells 
were pre-incubated for 30 min in the absence (open symbol) and presence (closed 
symbol) of cytidine 1 mM and incubated at different times with 50 µM [2-14C] 
uridine (5,600 dpm/nmol). Number of experiments (n): n = 3 (control); n = 3 (cyt 1 
mM). 
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 DISCUSSION 
 
 
Purine and pyrimidines are emerging as physiological regulators of a number of 
cellular functions such as cell growth, differentiation and cell death, and release of 
hormones, neurotransmitters and cytokines. As a consequence of such a wide 
physiological involvement, it is also becoming evident that alterations in the 
physiology of purinergic signalling may result in the development of a variety of 
pathologies, including immune system diseases, infiammation and pain, 
neurodegenerative disorders and osteoporosis. There are reports suggesting 
protective roles for purines and pyrimidines in various pathological conditions 
ranging from cancer, to ischemia-associated injury, traumatic tissue damage, bone 
resorption, stress and haemorrhagic shock (Abbracchio and Burnstock, 1998; 
Ciccarelli et al., 2001; Pizzorno et al., 2002). 
Mitochondrial oxidative phosphorylation, along with glycolysis, is essential for 
the maintenance of brain ATP levels. The depletion in cellular energy sources and 
reduction of ATP synthesis during ischemia or brain insults cause the loss of cellular 
homeostasis, which eventually leads to irreversible cellular damage. Growing lines 
of evidence indicate that purine nucleosides exert a neuroprotective effect. However, 
still matter of debate is whether their protective action is exerted through a receptor-
dependent (Abbracchio and Burnstock, 1998; Rathbone et al., 1999; Ciccarelli et al., 
2001; Shen et al., 2005; Pizzorno et al., 2002; Pooler et al., 2005) or receptor-
independent mechanism (Haun. et al., 1996; Jurkowitz et al., 1998; Yoo et al., 2005; 
Giannecchini et al., 2004; Choi et al., 2006; Balestri et al., 2007). Some papers have 
shown that adenosine protects neural cells during hypoxia/ischemia in vivo and in 
vitro (Ribeiro et al., 2002; van Calker and Biber, 2005; Rathbone et al., 1999). Many 
neuroprotective effects of adenosine appear to be mediated via adenosine A1 and A2 
receptors, whereas other protective effects occur by receptor-independent 
mechanisms. In contrast with adenosine, there are very few studies on the effects of 
exogenous inosine and guanosine during hypoxia/ischemia in brain in vitro or in 
vivo.  
In a receptor independent mechanism, nucleosides, that act after their entry into 
the cells, can be regarded as carriers of sugar that is made available through the 
action of nucleoside phosphorylases; in fact, without energy expense, a 
phosphorylated compound (Rib-1-P) is generated, which through the pentose 
phosphate pathway and glycolysis may be converted to energetic intermediates that 
can be utilized as energy source. In particular, purine or pyrimidine nucleosides 
could be phosphorolyzed to ribose l-phosphate and purine and pyrimidine base 
respectively, by purine/pyrimidine nucleoside phosphorylase. Three ribose l-
phosphates are isomerized to ribose 5-phosphate, and then converted to two glucose 
6-phosphates and one glyceraldehyde 3-phosphate, via transaldolases and 
transketolases of the pentose phosphate pathway. These phosphorylated 
intermediates enter the glycolytic pathway, yielding a net production of eight 
molecules of ATP per three molecules of ribose 1-phosphate (Fig.23) (Jurkowitz et 
al., 1998). 
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Fig.23. Schematic illustration of the putative metabolic fate of the pentose moiety of 
purine and pyrimidine nucleosides 
 
In this regard, although glucose represents the major energy source for neuronal 
cells, when the glucose supply is lowered and the oxygen is not sufficient to support 
mitochondrial respiration (ischemic and/or hypoxic conditions), nucleosides may 
become one of the major energy sources for the cell. Indeed, the nucleic acids that 
are released by dead cells during hypoxic/ischemic conditions are subjected to 
degradation, and therefore might provide a discrete amount of purine and pyrimidine 
nucleosides.  
The results reported in this research project clearly demonstrate that inosine, 
adenosine and guanosine are able to restore the ATP pool in ADF cells subjected to 
mitochondrial inhibition by oligomycin. In our experimental simil-ischemic 
conditions, the formation of lactate in the incubation medium indicates that purine 
nucleosides, like glucose, are utilized as energy source through anaerobic glycolysis. 
On the other hand, hypoxanthine and ribose are not able to restore the ATP levels, 
thus pointing to a relevant role of the phosphorolytic cleavage of nucleosides which 
generates, without energy expense, the phosphorylated pentose, which through the 
pentose phosphate pathway and glycolysis can be converted to energetic 
intermediates. ADF cells have high purine nucleoside phosphorylase activity (Fig. 
23).  
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Several reports indicate that pyrimidines play an important role for the 
maintenance of normal activity of the central nervous system (Loffler et al., 2005), 
and UTP has been demonstrated to act through pyrimidinergic receptors 
(Brunschweiger et al., 2006). In this research project, we show that also pyrimidine 
nucleosides, such as uridine and, to a lesser extent, cytidine exert a rescuing effect on 
cells previously subjected to mitochondrial inhibition. In fact, ADF cells express 
uridine phosphorylase activity, that makes the phosphorylated ribose moiety of 
uridine available for energetic purposes. Owing to the lack in mammals of a 
phosphorolytic activity on cytidine (Barsotti et al., 2002), this nucleoside must be 
deaminated to uridine, in order to make its ribose moiety available for energy 
repletion. Therefore, the low cytidine deaminase activity might account for the 
incomplete recovery when cytidine is present. Again, the formation of lactate 
indicates that pyrimidine nucleosides are utilized as energy source through anaerobic 
glycolysis. Our findings, which indicate the beneficial effect of pyrimidine 
nucleosides on ischemic neuronal cells, exerted through the restoration of the ATP 
pool, are in line with recent observations (Choi et al., 2006), in which uridine has 
been reported to prevent the glucose deprivation induced death of immunostimulated 
astrocytes, and point to a relevant role of uridine phosphorolysis. In fact, while for 
purine nucleosides different from adenosine, several authors postulate that an 
interaction of these nucleosides with purinergic receptors might account for their 
effect (Hasko et al., 2004; Shen et al., 2005), a similar receptor-dependent 
mechanism is unlikely to occur for pyrimidine nucleosides. Indeed, although 
postulated (Connolly et al., 1997), the presence of a receptor specific for uridine has 
never been demonstrated. Furthermore, our observation that PTAU, a potent inhibitor 
of uridine phosphorylase, significantly reverses the protective effect of uridine on 
ADF cells subjected to mitochondrial inhibition, is in agreement the relevant role 
exerted by this enzyme which produces the phosphorylated pentose, necessary for 
the restoration of ATP levels. Our hypothesis of a receptor-independent nucleoside 
effect is further supported by the finding that NBTI, an inhibitor of nucleoside 
transport, significantly reduces the protective action of inosine, adenosine, and 
uridine, while no effect is observed with glucose. 
Under diverse ATP depleting conditions, such as ischemia, astrocytes have been 
reported to release ATP, which is subsequently extracellularly hydrolyzed to 
adenosine, which may exert its hormone-like action interacting with specific 
membrane receptors. On the other hand, the bidirectional equilibrative nucleoside 
transport supplies a system for a re-entry of adenosine into the cell, where the 
nucleoside can be readily metabolized to AMP by adenosine kinase or to inosine by 
adenosine deaminase. As adenosine kinase requires ATP as a phosphate donor, 
adenosine deaminase is likely the most important enzyme for adenosine metabolism 
during ischemia conditions, therefore generating inosine which, as indicated in this 
research project, may well contribute to the maintenance of the ATP pool, thus 
improving cell viability.  
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The results reported in this thesis indicate that the protective effect of adenosine 
appears to be receptor-independent, and therefore, conceivably related to its 
intracellular conversion into inosine through the action of adenosine deaminase 
(which is present in ADF cells), as previously reported in different experimental 
models (Haun et al., 1996; Jurkowitz et al., 1998; Shin et al., 2002; Yoo et al., 
2005). In fact adenosine is able to restore the ATP pool independently of the 
presence of DPCPX which is an antagonist of adenosine receptors.  
Furthermore, the lack of protective effect exerted by adenosine when ADF cells 
subjected to mitochondrial inhibition are incubated in the presence of 
deoxycoformycin, the inhibitor of adenosine deaminase, clearly supports the relevant 
role exerted by this enzyme. It is worth noticing that inosine concentrations near 
millimolar have been reported in human brain (Traut, 1994), and therefore, this 
nucleoside might be considered as a suitable energy source for neuronal cells. 
Furthermore, our observations indicate that in the experimental simil-ischemic 
conditions adopted in the present work, a correlation exists between the restoration of 
the ATP pool, operated by purine and pyrimidine nucleosides, and cell viability. 
Deoxyinosine does not act as a neuroprotective compound, thus confirming a 
finding reported for a different experimental cell model (Giannecchini et al., 2004). 
Since purine nucleoside phosphorylase acts equally well on both ribo- and 
deoxyribonucleosides, once deoxyinosine enters the cells, deoxyRib-1-P is 
generated, which is then converted to deoxyRib-5-P by phosphopentomutase. 
DeoxyRib-5-P, in turn, may be cleaved into acetaldehyde, that can be converted to 
acetyl-CoA, and therefore, be used as energetic substrate only in the presence of 
oxygen, and glyceraldehyde-3-P that through glycolysis may generate ATP also in 
anaerobic conditions (Fig. 23). The lack of effect of deoxyinosine on the preservation 
of the ATP pool may be explained by the low deoxyriboaldolase activity present in 
ADF cells, which is probably inadequate to provide an amount of glyceraldehyde-3-
P sufficient for the maintenance of the ATP pool. 
In conclusion, while indicating that both purine and pyrimidine nucleosides exert 
a neuroprotective action by preserving the ATP pool in astrocytoma cells subjected 
to ischemic conditions, our data also support the hypothesis that their action relies on 
a receptor-independent mechanism. 
It is generally accepted that only liver and kidney maintain the de novo pyrimidine 
and purine synthesis and supply other tissues and organs, including brain, where the 
salvage synthesis is more active than the de novo synthesis, with preformed 
pyrimidine nucleosides (mainly uridine) and purine nucleosides and bases for 
nucleotide synthesis (Barsotti et al., 2002; Cao et al., 2005; Cansev, 2006). 
Therefore, another purpose of this research project is to study how do these districts, 
which rely more heavily on salvage synthesis, maintain the right balance between the 
purine and pyrimidine pools for the stability of genetic information. In this regard, 
we have hypothesized that the UPase–UK enzyme system, which maintains uridine 
homeostasis, could regulate the two processes of purine and pyrimidine salvage. 
Uridine kinase is the major entry step in the salvage of preformed uridine to UTP, 
and then to CTP, while the phosphorylase is the major entry step in the catabolism of 
uridine to β-alanine, a process considered to be restricted to the liver (Loffler et al., 
2005).  
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UK is inhibited by elevated UTP and CTP levels, a signal of pyrimidine 
sufficiency, and activated by ATP, a signal of purine sufficiency (Suzuki et al., 
2004). This kind of regulation is reminiscent of that exerted by UTP and CTP, acting 
as inhibitors, and ATP, acting as activator, on carbamoylphosphate synthetase and 
aspartate transcarbamylase, the committed steps of de novo pyrimidine biosynthesis 
in mammalian and bacterial cells, respectively (England and Herve, 1994). Uridine 
could represent a link between the purine and pyrimidine salvage synthesis (Cao et 
al.., 2005).  
In fact, the phosphorylated pentose stemming from uridine phosphorolysis, is a 
substrate of PRPP synthase which, in the presence of ATP, can converted the sugar 
into PRPP. PRPP is an essential compound for the salvage pathway of purine which 
is realized at the purine base level or maybe used itself for the salvage of pyrimidine 
nucleosides which is realized at the nucleoside levels. Adenine and hypoxanthine, in 
the presence of PRPP, are substrates of adenine phosphoribosyltransferase (APRT) 
and hypoxanthine-guanine phosphoribosyltransferase (HPRT), which catalyze the 
formation of adenosine and inosine monophosphate, respectively (purine salvage 
pathway). On the other hand, uridine can be both phosphorolytically cleaved by 
uridine phosphorylase (UPase) to ribose-1-phosphate (Rib-1-P) and the uracil base, 
or can be converted by uridine kinase (UK) into uridine nucleotides (pyrimidine 
salvage pathway) (Fig. 24).  
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Fig.24. Interrelationship between purine and pyrimidine salvage. The enzymes 
participating in the pathway are: 1.purine nucleoside phosphorylase; 2.Upase; 3.UK; 
4.nucleoside-monophosphate kinase; 5.nucleoside-diphosphate kinase; 
6.phosphopentomutase; 7.PRPP synthetase; 8.phosphoribosyltransferases; 9.cytidine 
deaminase; 10.adenosine deaminase. 
 
 
Previous experiments performed in this laboratory using rat brain extracts 
revealed that purine and pyrimidine salvage might be reciprocally regulated (Balestri 
et al., 2007). In particular, when the concentration of UTP and CTP is relatively 
high, the inhibition of UK causes a shift of the equilibrium of the reversible UPase 
reaction towards uridine phosphorolysis. The Rib-1-P formed is then converted into 
PRPP, which is used in the salvage synthesis of purine nucleotides which is favoured 
over pyrimidine salvage. Conversely, when the concentration of UTP and CTP is 
relatively low, the fully active UK, which catalyzes a virtual irreversible reaction, 
drives uridine towards uridine nucleotide formation, thus pyrimidine salvage is 
favoured over purine salvage (Fig.25).  
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Fig.25 Total pyrimidine and purine nucleotides salvaged at two [ATP]/[UTP] + 
[CTP] ratios (from Balestri et al., 2007). 
 
The experiments performed in our cell model are in agreement with these 
previous observations and explain how extracellular added nucleoside could regulate 
the purine and pyrimidine nucleotides production (Fig.25). 
In cultured ADF cells, exogenous uridine and, to a lesser extent inosine, are able 
to increase the total adenine nucleotide formation in a concentration-dependent 
manner as observed in the case of uridine. Moreover, uridine is also able to activate 
the salvage of exogenous hypoxanthine. When uridine accumulates, also in view of 
the inhibition exerted on UK by the raise of pyrimidine nucleotides, more Rib-1-P 
becomes available, through the action of UPase, for the PRPP-mediated adenine 
salvage. The fact that in the presence of PTAU, the inhibitor of uridine 
phosphorylase, the activation of adenine salvage by uridine is significantly lowered, 
confirms the relevant role exerted by the phosphorolysis of the nucleoside in order to 
donate the ribose moiety which can be converted by the cell, into PRPP. In this 
regard, also inosine, which, through purine nucleoside phosphorylase, acts as Rib- 1-
P donor, appears to stimulate adenine salvage. The highest amount of adenylate pool 
formed is observed when uridine is present.  
In fact, the phosphorolysis of inosine and guanosine, besides Rib-1 P, produces 
also hypoxanthine and guanine, respectively, which are converted, in the presence of 
PRPP, to IMP and GMP by hypoxanthine-guanine-phosphoribosyl transferase (Fig. 
24). Therefore, a certain amount of PRPP which derives from inosine or guanosine 
catabolism, can be utilized in this reaction, while in the presence of uridine, the 
whole PRPP formed by the phosphorylated pentose derived from the uridine 
catabolism, is utilized to produce the adenine nucleotide pool. In the presence of 
cytidine only a slight activation of the adenine nucleotide production was observed. 
This result may be explained by the low cytidine deaminase activity measured in 
ADF cells: in mammals, cytidine phosphorylase is absent, therefore cytidine can 
donate the ribose moiety only after its conversion to uridine by cytidine deaminase.  
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We have also showed that dIno has no effect on adenine salvage. Since deoxyRib-
5-P is not a substrate of PRPP synthetase, the lack of effect of deoxyinosine is a 
further indication that the salvage of the purine ring occurs at the nucleobase level, 
using PRPP as the donor of the phosphoribosyl moiety. In addition, the increased 
utilization of PRPP exerted by added adenine, might further favour uridine 
phosphorolysis, thus explaining the apparent inhibition exerted by adenine on 
exogenous uridine salvage to uracil nucleotides. We emphasize that adenine, even at 
1 mM, does not inhibit uridine transport (Crawford et al., 1998).  
On the other hand, we have also demonstrated that the purine inosine stimulates 5-
FU activation and uracil salvage: most likely, this occurs through a Rib-1-P-mediated 
process, because uracil phosphoribosyltransferase is absent in mammals (Cappiello 
et al., 1998). However, it cannot be excluded a priori that 5-FU activation might 
occur through the PRPP-mediated process, catalyzed by orotate 
phosphoribosyltransferase acting on 5-FU (Mascia and Ipata, 2001). Again, 
deoxyinosine has no effect on pyrimidine salvage.  
In order to investigate the effect of pyrimidine nucleotide level variation on the 
adenine salvage, ADF cells were enriched with CTP by pre-incubation with cytidine. 
In fact, cytidine enters the cells and is converted into CTP (in a concentration-
dependent manner) which inhibits UK. This inhibition causes a shift of the 
equilibrium of the reversible UPase reaction towards uridine phosphorolysis. The 
Rib-1-P formed is then converted into PRPP, which is used for the purine salvage 
(Fig.24). Therefore, an activation of adenine salvage is observed; conversely, when 
the concentration of CTP is relatively low, the fully active UK, which catalyzes a 
virtual irreversible reaction, drives uridine towards uridine nucleotide formation, thus 
lowering the rate of purine synthesis (Fig. 24). 
In conclusion, the ribose phosphate stemming from the phosphorolysis of purine 
and pyrimidine nucleosides not only can be converted into energetic intermediates in 
order to restore the ATP pool during cellular stress but it can be considered a link 
between the purine and pyrimidine salvage; these two processes are regulated at the 
level of UPase–UK enzyme system by the relative pyrimidine nucleoside 
triphosphate concentration. 
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